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Faithful chromosome segregation with bipolar spindle formation during cell division 
is critical for the maintenance of genomic stability. In mitosis, the centrosome is the 
main microtubule-organizing center (MTOC). Centrosome abnormality results in 
chromosome instability and aneuploidy, contributing to tumorigenesis. Polo-like 
kinase 1 (PLK1), a master cell cycle regulator, is actively involved in centrosome 
maturation, separation and the formation of bipolar spindle. Yet, the role of PLK1 in 
centrosome regulation is not fully understood. Mixed Lineage Leukemia 5 (MLL5) 
was identified in a screening for potential myeloid leukemia tumor suppressor genes, 
playing critical roles in hematopoiesis, epigenetics and cell cycle regulation. Recently, 
MLL5 was demonstrated to ensure mitotic fidelity by stabilizing the chromosomal 
passenger complex (CPC) at the kinetochore. However, mechanisms by which MLL5 
maintains genomic stability remain largely unknown. 
 
This work initiated from the finding that the multipolar spindle formation in MLL5-
knockdown (MLL5-KD) cells could not be rescued by the restoration of CPC level. 
This suggests a CPC-independent role of MLL5 in spindle pole regulation. We 
identified MLL5 as a novel centrosome component required for bipolar spindle 
formation. Moreover, MLL5 was indispensable for the prevention of aberrant 
cytosolic aggregation of PLK1. Knockdown of MLL5 caused PLK1 cytosolic 
aggregation and partial dissociation from the centrosome, which were involved in 
acentrosomal MTOC (aMTOC) formation, resulting in spindle multipolarity. 
Moreover, cytosolic MLL5 but not centrosomal MLL5 was required for the 
prevention of aberrant PLK1 aggregation and subsequent multipolar spindle 
 iv 
 
formation. Further molecular studies revealed that PLK1 bound to the Thr887-
Ser888-Thr889 motif on MLL5 through its PBD. PLK1 also phosphorylated MLL5 
on Ser-861, which was independent of the PBD binding. Importantly, the PLK1 PBD 
binding to MLL5 was essential for both PLK1 proper subcellular localization and 
bipolar spindle formation. Overexpression of wild-type MLL5 was able to rescue 
PLK1 aberrant aggregation and the formation of aMTOCs in MLL5-KD cells, while 
MLL5 mutant incapable of binding to the PBD failed to do so.  
 
Thus, we propose MLL5 as a novel centrosomal protein, maintaining spindle 
bipolarity through facilitating the incorporation of PLK1 to the centrosome via 
keeping PLK1 in a non-aggregated form during mitosis. Findings in this thesis extend 
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CHAPTER 1 – INTRODUCTION 
 
1.1    Mitosis 
1.1.1  An overview  
First observed by Robert Hook in 1665, the cell is the basic unit of all living 
organisms. When living things grow, develop or reproduce, they inevitably undergo 
the cell cycle, during which hereditary material replicates and partitions. DNA 
replication occurs during S phase, one restricted period of interphase. Separation of 
the duplicated DNA as well as the cell takes place in mitosis, or M phase. During G1 
phase, the gap between M phase and S phase, cell grows in size with mRNA 
synthesis, getting ready for the subsequent replication process. Similarly, during G2 
phase, the final stage of interphase, which is after S phase but before M phase, cell 
grows with protein synthesis, preparing itself for mitosis (Nurse, 2000). Mitosis is the 
most spectacular event of the cell cycle with spindle formation, chromosome 
segregation and division into two daughter cells. Although it is relatively short 
compared to interphase, there are five stages of M phase, which are prophase, 
metaphase, anaphase, telophase and cytokinesis (Figure 1.1). Prophase is the very 
start of mitosis. Chromosome condenses and the two centrosomes separate. 
Subsequently, during prometaphase, microtubules originating from the centrosome 
invade the nuclear area and capture each chromatid pair at the kinetochore. Motor 
proteins on the microtubules then provide pulling force towards opposite ends of the 
cells and the chromosomes are aligned along the equatorial plate. The formation of 
bipolar spindle with aligned chromosomes marks metaphase. Once all kinetochores 
are properly attached to microtubules, the spindle assembly checkpoint (SAC) signal 




is quenched and the cell proceeds to anaphase. Cohesin connecting the sister 
chromatids is cleaved. The two daughter chromosomes are pulled apart by shortening 
of the kinetochore microtubule. During telophase, chromosome decondenses and 
nuclear envelope reassembles. Cytokinesis is the last stage of mitosis, which gives 
rise to two daughter cells with the formation of cleavage furrow (Nath et al., 2015). 
 
 
Figure 1.1 Different stages in mitosis. Prophase: chromosome condenses and the 
two centrosomes separate. Prometaphase: microtubules search and capture each 
chromatid pair at the kinetochore. Metaphase: bipolar spindle is formed and 
chromosomes are aligned along the equatorial plate. Anaphase: cohesin is cleaved and 
the two daughter chromosomes are pulled apart. Telophase: chromosome decondenses 
and nuclear envelope reassembles. Figure was modified with permission from 
(Walczak et al., 2010). 
 
 
1.1.2  Mitosis and aneuploidy 
The whole process of mitosis is highly regulated in a sequential manner to achieve 
supreme fidelity without any segregation errors. Therefore, impairment of such 
fidelity may result in chromosome instability (CIN) or aneuploidy, which is a 
hallmark of cancer (Holland and Cleveland, 2009; Holland and Cleveland, 2012; Pfau 
and Amon, 2012). Generally, aneuploidy is the consequence of chromosome mis-
segregation. In specific, dysfunction of SAC, merotelic kinetochore attachment, 
cohesion defect and multipolar spindle with aberrant centrosomes are the major 
sources of aneuploidy (Nath et al., 2015).  
 
The SAC monitors the attachment of kinetochore to microtubules and remains 
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activated until all the kinetochores are correctly attached. The satisfaction of SAC 
initiates anaphase, during which securin is degraded by anaphase-promoting 
complex/cyclosome (APC/C) mediated proteolysis. Subsequently, activated separase 
cuts cohesin and the two sister chromatids, which now are daughter chromosomes 
separate under the microtubule pulling force from the two ends (Musacchio and 
Salmon, 2007). A number of proteins such as Mad and Bub family proteins forming 
mitotic checkpoint complex (MCC) and inhibiting APC/C are involved in the 
regulation of SAC. Altered expression of those proteins is believed to result in SAC 
defect, leading to aneuploidy (Holland and Cleveland, 2012). However, even with 
functional SAC, merotelic attachment of kinetochore, where microtubules from both 
spindle poles capture one single kinetochore, is able to cause aneuploidy. Aurora B 
kinase, mitotic centromere-associated kinesin (MCAK) and the chromosomal 
passenger complex (CPC) are all involved in this process. Overexpression of these 
proteins is common in cancer cells (Cimini et al., 2001; Cimini, 2008). In addition, 
cohesin abnormality caused by either mutation in gene encoding subunit of cohesin 
complex or overexpression of cohesin regulators such as securin and separase also 
gives rise to aneuploidy (Solomon et al., 2011). The last major cause of aneuploidy is 
centrosome abnormality accompanied with spindle multipolarity during mitosis, 
which will be discussed in detail in Chapter 1.2.3.  
 
As mentioned above, merotelic attachment of kinetochore requires CPC. The 
chromosomal passenger complex (CPC) is comprised of Aurora B kinase and three 
non-enzymatic regulatory subunits, Survivin, Borealin and INCENP (Ruchaud et al., 
2007). As the CPC level is cell cycle dependent and peaks at M phase, it is pivotal for 
chromosome organization, kinetochore-microtubule interaction and SAC activation at 




the inner centromere or at the kinetochore (Zhao et al., 2000; Honda et al., 2003). The 
central role of CPC during mitosis is the maintenance of mitotic fidelity and genomic 
stability by correcting kinetochore-microtubule attachment error. CPC reduces the 
stability or affinity of the kinetochore-microtubule interaction via Aurora B 
phosphorylating Hec1/Ndc80 complex and MCAK, which enables reattachment of 
microtubules to the kinetochore (DeLuca et al., 2006; Knowlton et al., 2006). 
Moreover, CPC regulating BubR1 level at the kinetochore directly activates SAC 
(Ditchfield et al., 2003; Morrow et al., 2005). Within the complex, the four 
components interact with each other extensively. Borealin and Survivin form 
subcomplex, interacting with INCNEP. In addition, Survivin binds to all the other 
subunits of CPC (Zhou et al., 2009). CDK1 phosphorylating Aurora B promotes the 
interaction between the centromeric adaptor, Shugoshin and Aurora B, which targets 
CPC to the centromere (Tsukahara et al., 2010; Yamagishi et al., 2010). In addition, 
phosphorylation of histone H3 on Thr-3 by Haspin recruits another subunit of CPC, 
Survivin to the centromeric region of the chromatin (Kelly et al., 2010; Wang et al., 
2010). Interestingly, depletion of any of the four components by RNAi makes the 
whole CPC unstable and dissociated from the kinetochore (Honda et al., 2003; Klein 
et al., 2006). Collectively, CPC plays crucial roles in chromosome organization, 
kinetochore-microtubule interaction and SAC activation during mitosis. 
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1.2    The centrosome 
1.2.1  An overview 
The centrosome is the main microtubule-organizing center (MTOC) during mitosis in 
animal cells. In interphase, the centrosome also nucleates cytoplasmic microtubule, 
regulating cell polarity and motility. The centrosome is composed of two orthogonally 
arranged mother-daughter centrioles as the core structure surrounded by a cloud of 
highly ordered pericentriolar material (PCM). One centriole is made up with nine 
microtubule triplets arranged in a cartwheel structure. Besides centrin, cenexin and 
tekin, the mother centriole contains additional docking appendages for cytoplasmic 
microtubules binding (Figure 1.2). The centriole microtubules are extremely stable, 
resistant to cold and detergent treatment. PCM consists of a number of proteins 
mainly responsible for microtubule nucleation and anchoring, including γ-tubulin, 
pericentrin and different kinds of kinases such as Polo-like kinase 1 (PLK1) and 
Aurora A kinase. γ-tubulin is the core component of the γ-tubulin ring complex 
(γTuRC), which nucleates microtubules and makes the centrosome function as the 
MTOC. The nucleation of microtubules or the organization of spindle at the 
centrosome is promoted by PLK1 and Aurora A (Bettencourt-Dias and Glover, 2007). 
Details of PLK1 function at the centrosome will be discussed later in Chapter 1.3. 
Besides the critical function of the centrosome during mitosis, the centriole also 
serves as a basal body for cilia and flagella to grow from, which plays vital roles in 














Figure 1.2 Schematic view of the centrosome. The centrosome is comprised two 
orthogonally arranged centrioles surrounded by a cloud of PCM. Both the mother 
centriole and the daughter centriole connected by linkers are made up with nine 
microtubule triplets. The docking appendage on the mother centriole is for 
cytoplasmic microtubule binding upon mitosis. Figure is modified with permission 




1.2.2  The centrosome cycle  
Like the cell cycle, the centrosome also undergoes a cycle. Moreover, the centrosome 
cycle coordinates with the cell cycle and is regulated by phosphorylation and 
proteolysis. There are four major events during a centrosome cycle: centriole 
disorientation, centrosome duplication, centrosome maturation and centrosome 
separation (Figure 1.3). After mitosis, each of the two daughter cells starts with one 
pair of centrioles. During G1 phase, the linker connecting the mother and the daughter 
centrioles is cleaved by separase and substituted with a relatively loose fibrous 
structure (Tsou et al., 2009). Similar to DNA duplication, centrosome also duplicates 
in S phase. New centrioles are formed near the proximal end of the original two 
centrioles and elongate throughout S and G2 phase until full length is reached. In the 
meantime, the old daughter centriole becomes a new mother centriole and each pair of 
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centiroles form a diplosome. PLK4, the most structurally divergent Polo-like kinase 
(PLK) family protein, initiates centriole assembly and ensures the precise duplication 
of centrosome in cooperation with CDK2, CP110 and Hs-SAS6 (Habedanck et al., 
2005). Both PLK4 phosphorylating of STIL and STIL binding to the polo-box 3 of 
PLK4 are required for centriole duplication (Arquint et al., 2015). Interestingly, 
overexpression of PLK4 causes centriole over-duplication leading to multiple 
centrioles while knockdown of PLK4 by siRNA transfection was able to eliminate the 
centriole resulting in centrosome-null cells (Habedanck et al., 2005; Holland et al., 
2012). Recently, reversible centrosome depletion in human cells could be achieved by 
inhibition of PLK4 (Wong et al., 2015).  
 
During centrosome maturation, which occurs just before mitosis, large amount of 
PCM proteins are recruited to the centrosome. Accumulation of γ-tubulin and 
subsequent formation of γ-TuRCs dramatically increase the microtubule nucleating 
activity of the centrosome. Meanwhile, immature mother centriole acquires 
maturation marker such as ninein. Centrosome maturation is heavily dependent on 
phosphorylation by PLK1 and Aurora A. The role of PLK1 in centrosome maturation 
will be discussed later in Chapter 1.3. Aurora A activates the phosphatase CDC25B by 
phosphorylation at the centrosome, which further activates CDK1 contributing to 
mitotic entry (Dutertre et al., 2004). To recruit γ-tubulin to the centrosome promoting 
microtubule nucleation, Aurora A phosphorylates and activates LATS2 (Toji et al., 
2004). Moreover, Aurora A stabilizes centrosomal microtubules by phosphorylating 
the centrosomal adaptor TACC3 in a clathrin-dependent manner (Fu et al., 2010).  
 
Upon mitosis, the centrosome cohesion is destroyed and the two centrosomes are 




pulled apart by the motor protein, dynein. Nek2, PLK1, CDK1 and Aurora A all are 
involved in the regulation of centrosome separation. Overexpression of Nek2 causes 
centriole separation even in interphase, while kinase-dead Nek2 results in monopolar 
spindle formation due to defective centrosome separation (Faragher and Fry, 2003). 
Nek2 promotes premitotic centrosome separation by displacing centrosomal linker 
proteins such as C-Nap1, rootlein, LRRC34 and β-catenin from the inter-region of 
parental centrioles (Fry et al., 1998; Faragher and Fry, 2003; Bahmanyar et al., 2008; 
He et al., 2013). PLK1 contributes to centrosome separation by phosphorylating and 
activating Nek9, which further activates Nek6. Nek6 then recruits the kinesin, Eg5 to 
the centrosome by directly phosphorylating Eg5 (Rapley et al., 2008; Bertran et al., 
2011). CDK1 not only phosphorylates Nek9, providing a docking site for PLK1, but 
also phosphorylates PP1γ to facilitate Nek2 centrosomal function (Dohadwala et al., 
1994; Mardin et al., 2011). Moreover, CDK1 ensures centrosome separation and 
spindle bipolarity by phosphorylating Eg5. This promotes Eg5 binding to antiparallel 
microtubules and moving towards the plus-end of microtubule (Smith et al., 2011). 
Since CDK1 activates Aurora A and Aurora A activates PLK1, the CDK1-AurA-
PLK1-Nek2 signaling cascade plays a critical role in regulating centrosome separation 
(Wang et al., 2014). Finally, after centrosome maturation and separation, bipolar 
spindle is formed between the two centrosomes (Meraldi and Nigg, 2002). 
 
  




Figure 1.3 The centrosome cycle.  Centrosome disorientation occurs in early G1 
phase. The linker connecting the mother and the daughter centrioles is cut and 
substituted by a relatively loose fibrous structure. During S phase, centrosome 
duplicates. New centrioles are formed near the proximal end of the original two 
centrioles and elongate afterward until full length is reached. In the meantime, the old 
daughter cell becomes a new mother centriole and each pair of centiroles form a 
diplosome. During centrosome maturation, which occurs just before mitosis, large 
amount of PCM proteins are recruited to the centrosome. The formation of γ-TuRC 
enables the centrosome to nucleate microtubule and organize mitotic spindle. Upon 
mitosis, the centrosome cohesion is destroyed and the two centrosomes are pulled 
apart by the motor protein, dynein. Finally, bipolar spindle is formed at metaphase. 
 
 
1.2.3  Centrosome abnormality and spindle multipolarity 
In 1888, when Theodor Boveri first described the importance of centrosome, CIN had 
already been thought to be a consequence of centrosome defect and be able to result 
in cancer. Indeed, centrosome abnormality together with CIN is observed in most 
carcinomas and sarcomas and is therefore a hallmark of cancer (Pihan et al., 1998; 
Chan, 2011). Yet, whether the defect in centrosome is a cause or a consequence of 
tumorigenesis has been a long-standing argument (Zyss and Gergely, 2009). However, 
evidence has been accumulated to support that centrosome abnormalities are the 
driving forces but not secondary effects of cancer developement, as in certain cancers 
centrosomal changes occur in the earliest stage of oncogenic transformation. 
Although both numerical alteration and structural defect of the centrosome are 




reported, supernumerary centrosomes are much more evident and widely studied 
(Pihan et al., 2003). In cell with supernumerary centrosomes, the mis-segregation of 
chromosomes resulting in CIN is mainly due to the multiple centrosomes organizing 
multipolar spindle.  
 
Multipolar spindle is strongly associated with supernumerary centrosomes due to 
centrosome amplification or loss of spindle pole integrity (Figure 1.4) (Maiato and 
Logarinho, 2014). Centrosome amplification may arise from centriole overduplication 
in S phase or de novo centriole assembly. Additionally, cytokinesis failure, mitotic 
slippage in late mitosis and cell fusion all lead to multiple centrosomes. (Holland and 
Cleveland, 2009; Kramer et al., 2011). In the presence of more than two centrosomes 
with two centrioles each, cells normally display multipolarity. However, clustering of 
multiple centrosome may occur, which prevents cell from multipolar spindles and 
further aneuploidy (Quintyne et al., 2005). Besides centrosome amplification, loss of 
spindle pole integrity also leads to supernumerary centrosomes with spindle 
multipolarity. Centriole disengagement normally occurs in early G1 phase as 
described above. However, during mitosis, when the tight connection between mother 
and daughter centrioles is destroyed due to the inefficient inhibition of separase, the 
two centrioles separate and multipolar spindle forms before chromosome segregation. 
In this case, each of the centrosomes after centriole splitting contains only one 
centriole. PCM is a highly ordered structure containing the γ-TuRC, which nucleates 
and anchors spindle microtubules during mitosis. Therefore, defects in the PCM may 
make the centrosome unable to withstand the pulling force generated by microtubule 
motor proteins and PCM therefore gets fragmented. Notably, newly formed spindle 
poles due to PCM fragmentation contain no centriole. Depletion of specific PCM 
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protein such as PCM-1, ninein and CLASP has been reported to cause multipolar 
spindle formation (Dammermann and Merdes, 2002; Delgehyr et al., 2005; Logarinho 
et al., 2012). Moreover, dysfunction of two key kinases, PLK1 and Aurora A or their 
associating PCM proteins also contributes to the loss of spindle integrity (Maiato and 






Figure 1.4 Multipolar spindle formation with or without centrosome 
amplification. Centriole overduplication in S phase and cytokinesis failure are two 
major mechanisms of spindle multipolarity with centrosome amplification. Centriole 
disengagement due to the improper cleavage of the centriole cohesion during mitosis 
and PCM fragmentation are two major mechanisms of spindle multipolarity without 









1.3    Polo-like kinase 1 
PLK family proteins are serine/threonine kinases sharing characteristic polo-box 
domain (PBD) at C-terminus, which is responsible for PLK interaction with other 
proteins and regulates the N-terminal kinase domain (Figure 1.5). They are key 
regulators of the cell cycle (especially mitosis and cytokinesis), the centrosome cycle 
and DNA damage response. Their highly dynamic abundance, conformation, activity 
and subcellular localization at different phase of the cell cycle indicate a tight 
regulation both temporally and spatially. Moreover, their associations with other 
proteins greatly contribute to crucial cell cycle events. PLK functions are altered in 
various cancers, which further indicates the importance of PLKs in cellular work as 
well as their potentials in cancer treatment (Zitouni et al., 2014).  
 
Among the five PLKs identified in human, PLK1 is the first and also the most 
extensively studied member in the family. The kinase activity of PLK1 is 
autoinhibited by the PBD. Such intramolecular interaction is disrupted by the 
phosphorylation of Ser-137 in the hinge region or of Thr-210 in the T-loop of 
catalytic domain by Aurora A together with Bora (Macurek et al., 2008; Seki et al., 
2008b; Xu et al., 2013). On the other hand, PLK1 promotes the degradation of Bora 
via phosphorylating its degron motif (Seki et al., 2008a). In fact, after PLK1 
activation, a minimal amount of residue Bora is sufficient to sustain PLK1 kinase 
activity during mitosis (Bruinsma et al., 2014). The PBD of PLK1 binds to phospho-
peptide with the optimal binding motif (Ser-[pSer/pThr]-[Pro/X], where X is any 
amino acid), which is phosphorylated by a pro-directed kinase such as CDK1, 
MAPKs or PLK1 itself forming a local feedback loop (Cheng et al., 2003; Elia et al., 
2003a; Elia et al., 2003b). The PBD binding to a phosphorylated protein further 
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relieves the kinase domain from the PBD inhibition and targets PLK1 to specific 
subcellular localization. The highly dynamic localization of PLK1 facilitates its 
multiple cellular functions. In interphase, PLK1 is present at the centrosome, in 
microtubules and the cytoplasm. Upon mitosis, PLK1 peaks in both expression and 
kinase activity and is recruited to the centrosome, the kinetochore and the midbody. 
Interestingly, when PLK1 localization at the centrosome or the kinetochore is 
impaired due to depletion of its interacting proteins such as SENP6 or NUMB, PLK1 
forms cytosolic aggregates (Mukhopadhyay and Dasso, 2010; Schmit et al., 2012). 
Finally, PLK1 is degraded by APC/C mediated proteolysis (Petronczki et al., 2008; 
Archambault and Glover, 2009).  
 
 
Figure 1.5 Primary structure of PLK1. The kinase domain is at N-terminus while 
the PBD composed of two polo-box motifs is at C-terminus. Activation of PLK1 is 
through phosphorylation of Ser-137 or Thr-210 in the kinase domain. The two 
domains are connected by an inter-domain linker harboring a destruction box. 
 
 
PLK1 is a major regulator of the cell cycle, involved in mitotic entry, G2/M 
checkpoint, spindle assembly, chromosome segregation, cytokinesis abscission etc. In 
addition, PLK1 is a master mediator of the centrosome. It promotes centrosome 
separation by destroying the link between the two centrosomes and coordinates the 
centrosome cycle with the cell cycle by regulating centriole disengagement (Zitouni et 
al., 2014). Inhibition of PLK1 activity causes monopolar spindle formation with γ-
tubulin dissociation from the centrosome and reduced microtubule-organizing activity 




(Lenart et al., 2007). Upon mitosis, centrosomal PLK1 recruits PCM proteins for γ-
TuRC assembly at the centrosome including Aurora A, pericentrin, CEP215 and so 
on. (Archambault and Glover, 2009). PLK1 also phosphorylates NEDD1 and HICE1, 
which promotes augmin-microtubule interaction, targeting the γ-TuRC to the 
centrosome (Luders et al., 2006; Zhang et al., 2009a). Moreover, the PLK1-NEDD1 
complex together with the PLK1 phosphorylating augmin enables microtubule-based 
microtubule nucleation (Johmura et al., 2011). PLK1 PBD binding to phospho-peptide 
has been shown to regulate PLK1 dynamic subcellular localization (Elia et al., 
2003a). However, the PBD of PLK1 appears to be dispensable during centrosome 
maturation (Hanisch et al., 2006). Therefore, how PLK1 itself is recruited to the 
centrosome remains elusive.  
 
 
1.4    Mixed Lineage Leukemia (MLL) protein family  
1.4.1  An overview 
The mixed lineage leukemia (MLL) family proteins are the mammalian homologues 
of the Drosophila trithorax group (TrxG) proteins. TrxG and their antagonistic 
counterpart, the polycomb group (PcG) proteins form large complex regulating other 
gene expression through chromatin remodeling and histone modifications at the 
epigenetic level (Muller et al., 2002; Schuettengruber et al., 2007). TrxG commonly 
serves as a gene activator while PcG is associated with gene silencing. One well 
studied target of TrxG and PcG is the Homeobox (Hox) gene, which encodes a much 
conserved class of transcription factors, playing pivotal roles in embryonic 
development and hematopoiesis (Svingen and Tonissen, 2006). Leukemia-associated 
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genetic lesions are able to result in aberrant Hox gene expression (Look, 1997; 
Dorrance et al., 2006). In addition, TrxG and PcG have also been suggested to affect 
cell proliferation in a Hox dependent or independent pathway. 
  
 
Figure 1.6 Schematic representations of MLL family proteins. The graph was 
constructed based on the domain analysis using SMART program (http://smart.embl- 
heidelberg.de/). The evolutionary relationship among MLL family members was 
drawn based on the cladogram from ClustalW (http://www.ebi.ac.uk/Tools/clustalw/) 
(Cheng et al., 2008). 
 
Five members have been identified in MLL protein family, which are MLL1, MLL2, 
MLL3, MLL4/ALR and MLL5 (Figure 1.6). They possess a variable number of 
cysteine-rich plant homeodomain (PHD) zinc finger and a highly-conserved Su(var)3-
9, enhancer-of-zeste and trithorax (SET) domain, both of which are involved in 
protein-protein interaction. The PHD finger has been found to be present in 
chromatin-associated proteins and to be able to bind modules for histone 
modifications, reading the histone code (Aasland et al., 1995; Mellor, 2006). The SET 
domain together with its surrounding sequences is responsible for the 
methyltransferase activity of MLL proteins (Kouzarides, 2002; Nakamura et al., 
2002). MLL1/ALL1 is the most widely studied member in the family. MLL1 fusion 
proteins are the result of chromosomal translocations, which affect the MLL1 proto-
oncogene at 11q23. They were discovered in myeloid and lymphoid leukemia 




(Ziemin-van der Poel et al., 1991). MLL2 is the closest homologue to MLL1, sharing 
the same interacting partners. MLL3 is more related to MLL4/ALR. They were found 
in ASC-2–containing co-activator complexes (ASCOM) (Goo et al., 2003). MLL5 is 
the latest addition into the family, which will be discussed in detail in Chapter 1.5. 
 
1.4.2  MLL protein family in epigenetics 
Due to the SET domain, MLL family proteins are the main H3K4-specific histone 
methyltransferases (HMTs) regulating embryogenesis, development and cell cycle 
progression. Biochemical reconstitution and crystal structure analysis have revealed 
that both MLL1 and MLL2 form histone lysine methyltransferase (HKMT) complex 
with WDR5, RbBp5, Ash2L and DPY-30 (WRAD) to regulate Hox gene expression 
(Hughes et al., 2004; Wysocka et al., 2005; Dou et al., 2006). The HKMT complex 
also contains human CpG binding protein, MOF (histone acetyltransferase), HCF1, 
HCF2 (host cell factor) and Menin (Yokoyama et al., 2004; Dou et al., 2005; Ansari et 
al., 2008). Moreover, menin-MLL1 interaction is required for MLL1-fusion-driven 
leukemogenesis (Yokoyama et al., 2005). Although Mll1-null mice are embryonic 
lethal due to the failure in the maintenance of Hox gene expression, mice harboring a 
homozygous MLL1 depleted of the SET domain are born at normal Mendelian ratios 
with mild phenotypes (Yu et al., 1998; Terranova et al., 2006). This suggests a HKMT 
activity independent role of MLL1 in chromatin regulation. The HKMT activities of 
MLL3 and MLL4 have been demonstrated to associate with H3 acetylation and 
H3K27 demethylation (Lee et al., 2007; Nightingale et al., 2007). Unlike MLL1 or 
MLL2, the WRAD sub-complex appears to be dispensable for MLL3 HKMT activity 
(Shinsky and Cosgrove, 2015). Similarly, MLL4 shows high intrinsic activity without 
WRAD due to its postSET loop region, which enables the SET domain to catalyze 
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multiple methylations on H3K4 (Zhang et al., 2015). 
 
1.4.3  MLL protein family in cell cycle regulation 
The dynamic association of MLL1 with chromatin has suggested its crucial role in 
cell cycle progression (Mishra et al., 2009). MLL1-null MEFs are impaired in 
proliferation (Takeda et al., 2006). SCFSkp2 and APCCdc20 mediated degradation of 
MLL1 at S phase and late M phase assures cell cycle execution (Liu et al., 2007). The 
precursor MLL1 and MLL2 are cleaved by an evolutionarily conserved protease, 
Taspase I and the cleaved active MLL1 and MLL2 directly target E2Fs for cyclin 
expression (Takeda et al., 2006). MLL1 also contributes to the mammalian DNA 
damage response pathway as well as the S-phase checkpoint. Phosphorylation of 
MLL1 by ATR disrupts MLL1 interaction with the SCFSkp2 E3 ligase, leading to its 
accumulation on chromatin (Liu et al., 2010a). During cell division, MLL1 associates 
with gene promoters packaged within condensed chromosomes and favors genes that 
are highly transcribed during interphase (Blobel et al., 2009). This suggests a novel 
function of MLL1-based gene regulation as mitotic bookmarking, which enables the 
cell to inherit active gene expression states during mitosis. Besides MLL1, MLL4 also 
maintains cell cycle progression and cell viability through regulating the expression of 
a number of key cell cycle regulators such as cyclin D, cyclin E, p27, HOXA5 and 
HOXB7 via histone H3K4 trimethylation (Ansari et al., 2012). 
 
 




1.5   Mixed Lineage Leukemia 5 (MLL5) 
1.5.1  An overview 
The MLL5 gene was identified in a screening for potential myeloid leukemia tumor 
suppressor genes from a ~2.5Mb region within chromosome band 7q22, which is 
frequently deleted in acute myeloid leukemia (AML) and therapy-induced myeloid 
neoplasms (Hasle et al., 1999; Emerling et al., 2002; Brezinova et al., 2007). It 
comprises of 25 exons and encodes MLL5 protein with 1,858 amino acids. RNA 
tissue arrays showed that MLL5 is ubiquitously expressed, with the highest levels in 
fetal thymus, kidney and in adult hematopoietic tissues. MLL5 is the mammalian 
homolog of Drosophila upSET (CG9007) and is evolutionarily the most distant 
member in the MLL family. It possesses only one PHD finger and one N-terminal 
SET domain with no AT-hooks or the methyltransferase homology domain. Although 
no mutations within the coding region or translocations of MLL5 have been detected 
in primary leukemia samples from patients, high MLL5 expression level is correlated 
with high overall survival and relapse-free survival (Emerling et al., 2002; Damm et 
al., 2011). This suggests the prognostic significance and the therapeutic potential of 
MLL5 in myeloid leukemia. However, Mll5-null mice are not embryonic lethal with 
no increased incidence of tumor. (Heuser et al., 2009; Madan et al., 2009; Zhang et 
al., 2009b). Yet, Zhang et al. observed postnatal lethality, retarded growth and a 
decrease of long-term hematopoietic stem cells (LT-HSC) in Mll5 deficient mice, 
where exon 3 and 4 of Mll5 was deleted. Moreover, Madan et al. discovered male 
sterility, reduced sizes of thymus, spleen and lymph node in Mll5-null mice. 
Additionally, Mll5 was needed to maintain the quiescent state of LT-HSC. Heuser et 
al. identified increased incidence of eye infection in Mll5-/- mice depleted of exon 3 of 
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Mll5, which was due to defects in neutrophils maturation. Mild growth retardation, 
male infertility together with compromised immunity were reported in Yap’s group. 
Besides, defects in both terminal maturation and the packaging of sperm with 
impaired motility were observed in Mll5 deficient mice (Yap et al., 2011). Taken 
together, Mll5 plays a pivotal role in hematopoiesis and spermatogenesis but not 
embryonic development. 
 
1.5.2  MLL5 and epigenetic control 
MLL5 localizes to the nucleus during interphase and dissociate from the chromosome 
upon mitosis, implicating a role of MLL5 in chromatin regulation (Deng et al., 2004). 
MLL5 is able to modulate H3K4 methylation indirectly by regulating the expression 
of histone modifying enzymes, LSD1 and SET7/9 (Sebastian et al., 2009). Structural 
study has shown that the PHD finger of MLL5 interacts with di- and tri-methylated 
histone H3K4, serving as a reader of H3K4 methylation marks. The PHD finger 
binding to H3K4me3 recruits MLL5 to gene-rich euchromatic regions for epigenetic 
regulation, while phosphorylation of H3T3 and H3T6 abrogates such association, 
releasing MLL5 from chromatin upon mitosis (Ali et al., 2013; Lemak et al., 2013). A 
recent study reported that MLL5 represses H3.3 expression and orchestrates global 
chromatin organization (Gallo et al., 2015). However, whether MLL5 possesses 
intrinsic HKMT activity is still under debate. This is probably because MLL5 lacks 
the postSET domain, known to be essential for methylation (Kouzarides, 2002). 
Recently, one N-terminal isoform of MLL5 (MLL5β, 503 amino acids) was identified. 
MLL5β activates E6/E7 oncogene transcription in HPV16/18 positive cervical cancer 
through the interaction with transcription factor AP-1 at the distal region of the 
HPV16/18 long control region (Yew et al., 2011). Moreover, O-GlcNAcylation of 




MLL5β is required for assembly of the MLL5β-AP-1 transcription complex at the 
long control region (Nin et al., 2015). Importantly, silencing of MLL5β in HPV16/18-
associated cervical cancers inhibits tumor growth and promotes cisplatin-like gamma-
irradiation sensitization, suggesting a therapeutic potential of MLL5β (Nin et al., 
2014). Collectively, the mechanisms of MLL5 as well as MLL5β in epigenetic 
regulation remain elusive. 
 
1.5.3  MLL5 and cell cycle regulation 
Overexpression of MLL5 has been shown to arrest cell cycle at G1 phase (Deng et al., 
2004). Additionally, siRNA-mediated knockdown of MLL5 results in retarded cell 
cycle and cell cycle arrest at both G1 and G2/M phase, possibly due to the up-
regulation of p21 and the dephosphorylation of Rb (Cheng et al., 2008). Down-
regulation of MLL5 by camptothecin contributes to p53 activation, indicating MLL5 
as a novel component in the regulation of p53 homeostasis (Cheng et al., 2011). 
MLL5 knockdown also delays the entry of quiescent myoblasts into S-phase, but 
hastens the completion of S-phase progression (Sebastian et al., 2009). Furthermore, 
CDK1-catalyzed phosphorylation of MLL5 on Thr-912 residue is required for mitotic 
entry (Liu et al., 2010b). Recent studies showed that MLL5 maintains genomic 
integrity during mitosis by maintaining the stability of the CPC at the kinetochore, a 
key regulator of chromosomal bi-orientation. Down-regulation of MLL5 causes 
chromosome misalignment due to CPC dissociating from the kinetochore, which 
results in DNA segregation defect and cytokinesis failure (Liu et al., 2012). Taken 
together, MLL5 is actively involved in cell cycle regulation, which strongly suggests 
a role of MLL5 in tumor suppression. 
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1.6 Aims and hypothesis of this study 
 
As a hallmark of tumorigenesis, genomic instability has been observed in various 
kinds of cancer and considered the driving force of tumor progression. Mll5 was 
identified as a potential tumor suppressor gene and demonstrated to regulate cell cycle 
progression. Both knockdown and overexpression of MLL5 caused cell cycle arrest 
(Emerling et al., 2002; Deng et al., 2004; Cheng et al., 2008). In addition, CDK1 
phosphorylating MLL5 is required for mitotic entry (Liu et al., 2010b). More 
importantly, MLL5 maintains mitotic fidelity by ensuring proper chromosome 
alignment during mitosis, which is achieved by its stabilization of CPC at the 
kinetochore (Liu et al., 2012). However, mechanisms on how MLL5 maintains 
genomic stability are not fully understood. This study aims to further reveal the role 
of MLL5 in tumor suppression during mitosis and to provide more evidence of how 
CIN is caused by abnormal mitosis, resulting in aneuploidy. Since the subcellular 
localization of endogenous MLL5 has not been comprehensively studied besides its 
dynamic nuclear localization during a cell cycle (Deng et al., 2004), this study also 
aims to elucidate the spatial organization of MLL5. 
 
This project initiated with the finding of two types of chromosome misalignment due 
to the degradation of CPC in MLL5-KD cell in mitosis: bipolar misalignment and 
multipolar misalignment. However, restoration of CPC level only corrected the 
bipolar misalignment but not the multipolar misalignment in MLL5-KD cells (Liu et 
al., 2012). These results suggest that MLL5 maintains the bipolarity of mitotic spindle 
in a CPC-independent manner and is very likely involved in centrosome regulation 
and spindle pole organization. With this hypothesis, we first examined the subcellular 




localization of MLL5 using immunofluorescence. Given that MLL5 is a novel 
centrosomal protein, the role of MLL5 in centrosome regulation was examined by 
down-regulation of MLL5, which revealed that the multipolar spindle formation in 
MLL5-KD cells was due to extra MTOC formation. Moreover, knockdown of MLL5 
also caused PLK1 dissociate from centrosome forming cytosolic aggregates, which 
were involved in the formation of additional MTOCs. Further molecular studies 
showed that PLK1 bound to MLL5 through the PBD and phosphorylates MLL5. 
Finally, rescue experiments demonstrated that the PLK1 PBD binding to MLL5 was 
essential for proper PLK1 subcellular localization and the bipolar spindle formation.  
 
Collectively, the study of MLL5 here reveals a novel role of MLL5 at the centrosome 
ensuring mitotic fidelity, which contributes to the maintenance of genomic stability.  
This work not only advances the understanding of tumorigenesis, but also sheds some 
light on the clinical relevance of MLL5 in human cancers. 
 
 




CHAPTER 2 – MATERIALS AND METHODS 
 
 
2.1 Cell culture and synchronization 
Human osteosarcoma U2OS (ATCC, HTB-96TM, Manassas, VA, USA), cervical 
carcinoma HeLa (ATCC, CCL-2TM, Manassas, VA, USA), embryonic kidney 293T 
(ATCC, CRL-3216TM, Manassas, VA, USA) and lung fibroblast WI-38 cells (ATCC, 
CCL-75TM Manassas, VA, USA) were cultured as monolayer in complete medium: 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich, D1152) 
supplemented with 10% FBS, 2 mM L-glutamine at 37°C in a humidified atmosphere 
of 5% CO2. Cells were routinely passaged once every two days with the use of 0.25% 
Trypsin-Ethylene-Diamine Tetracetic acid (EDTA). For WI-38, only low-passaged 
cells (less than 10 passages) were used.  
 
Synchronization to G2 phase was achieved by incubation with the complete medium 
containing 10 µM RO-3306 (217699, Calbiochem) for 16 h. Prometaphase 
synchronization was achieved by incubation with the complete medium containing 
100 ng/ml nocodazole (M1404, Sigma-Aldrich) or 10 µM monastrol (M8515, Sigma-
Aldrich) for 16 h. Cells arrested at prometaphase were harvested using the mechanical 
shake-off procedure. For metaphase arrest, prometaphase cells were released from 
nocodazole and incubated with the complete medium containing 20 µM MG132 
(474790, Calbiochem) for 90 min. 100 nM BI2536 (S1109, Selleck Chemicals) was 
applied to cells treated with nocodazole or MG132 for 90 min to inhibit PLK1 in 





mitosis. 0.5 µM MLN8237 (S1103, Selleck Chemicals) was applied to cells treated 
with nocodazole to inhibit Aurora A in mitosis. 10 µM RO-3306 was applied to cells 
treated with nocodazole to inhibit CDK1 in mitosis. 
 
2.2 RNA interference 
Down-regulation of MLL5 was achieved by transfection of MLL5 specific siRNA 
duplexes (#01, #02 and #03) targeting nucleotide positions at 1063, 5215 and 6807 
respectively, from the transcription starting point [National Centre for Biotechnology 
Information (NCBI) reference sequence: NM_182931.2]. Down-regulation of PLK4 
was achieved by transfection of PLK4 specific siRNA duplexes (#01 and #02) 
targeting nucleotide positions at 212 and 2913, respectively, from the transcription 
starting point (Habedanck et al., 2005). Scrambled siRNA (NC-siRNA) was used as 
control. All the siRNA duplexes were ordered from 1st BASE (Singapore) and the 
sequences are summarized in Table 1. Cells were seeded one day before transfection 
in complete medium to achieve cell confluency of 30% on the day of transfection. For 
one well of a 6-well plate, 1.5 µl of siRNA duplex (30 pmol) was diluted in 250 µl of 
serum-free DMEM and 4 µl of of Lipofectamine® RNAiMAX (13778150, Life 
technologies, Inc) was diluted in 250 µl of serum-free DMEM. The diluted siRNA 
was added into diluted RNAiMAX and the mixture was incubated at room 
temperature (RT) for 20 min followed by drop-wise addition onto the cell monolayer. 
 
  




Table 1: siRNA sequences 



















Sense 5’- AACUAUCUUGGAGCUUUAUAAdTdT-3’ 
Antisense 5’- UUAUAAAGCUCCAAGAUAGUUdTdT-3’ 
PLK4 #2 
(2913) 
Sense 5’- ACUCCUUUCAGACAUAUAAGdTdT-3’ 
Antisense 5’- CUUAUAUGUCUG AAAGGAGUdTdT-3’ 
 
 
2.3 DNA constructs and transfection 
FLAG-MLL5, truncated FLAG-MLL5 mutants and GST-fused FLAG-MLL5-CD4 
used in this study were constructed previously (Liu et al., 2010b). Briefly, PCR 
fragment of MLL5 cDNA flanked with the FLAG sequence were inserted to pEF6/V5-
His vector (K9610-20, Invitrogen) in frame with BamHI and XbaI sites. MLL5-CD4 
fragment with GST-tag fused at the N-terminal was cloned into the pGEX-4T3 vector 
(27-4583-01, Amersham Biosciences). GFP-α-tubulin was made previously 
constructed by lab member Liu Jie. α-tubulin was cloned to pEGFP-C1 vector 
(Clontech) in frame with HindIII and BamHI sites. 
 
Full-length PLK1 (NCBI Reference Sequence: NM_005030) was PCR-amplified 
from HeLa cDNA using Taq PCR Core Kit (201223, Qiagen). The PCR reaction was 
analysed by gel electrophoresis and the PCR product (1,812 bp) was purified from the 
agarose gel using the Gel Extraction Kit (Qiagen). Purified PCR product was digested 





with NotI and KpnI restriction enzymes (New England Biolabs) at 37°C for 6 h. 
Ligation of the PLK1 amplicon into the pXJ-HA vector (Manser et al., 1997) was 
performed using T4 DNA ligation mixture (New England Biolabs) at 1:10 (vector: 
insert) ratio at RT for 3 h. Sequencing of the constructs were performed by 1st BASE 
(Singapore). To ensure that there is no mutation during PCR and the reading is in 
frame, results were aligned against the original sequence using the Basic Alignment 
Search Tool (BLAST) from NCBI. 
 
Kinase-dead PLK1 (D194A), PBD-mutated PLK1 (H538A-K540M) mutants and all 
FLAG-MLL5-CD4 site-directed mutants were constructed using the QuikChange site-
directed mutagenesis kit (Stratagene). Mutagenic primers were designed according to 
the manufacturer’s instruction. Basically, primers between 25 and 45 bases in length 
contain the desired mutation and anneal to the same sequence on opposite strands of 
the plasmid. The melting temperature should be greater than 78°C estimated by the 
following formula: Tm = 81.5 + 0.41(%GC) − (675/N) − %mismatch, where N is the 
primer length in bases; %GC and %mismatch are whole number. Primer sequences 
were listed in Table 3 and the PCR condition were shown in Table 2. PCR products 
were digested by 1 µl of DpnI restriction enzyme (10 U/µl) (New England BioLabs, 
R0176) at 37°C for 1 h and transformed into competent cell E.coli DH5α. The final 
constructs containing the desired mutation were confirmed by DNA sequencing 
described above. 
  
DNA plasmid transfections were performed using the calcium phosphate method in 
293T cells. Cells were seeded one day before transfection in complete medium to 
achieve confluency of 40-60% on the day of transfection. For one well of a 6-well 




plate, 2 µg of DNA plasmid (> 100 ng/µl in dd H2O) was added to distilled water 
followed by drop-wise addition of 2.5M CaCl2 with final volume of 100 µl. This 
DNA-CaCl2 mixture was mixed gently and transferred drop-wise to 100 µl 2X HBS 
solution (280 mM NaCl, 50 mM HEPES, 1.42 mM Na2HPO4•7H2O, pH 7.05). This 
DNA-CaCl2–HBS mixture was mixed gently by pipetting up and down and incubated 
at RT for 30 min before adding drop-wise to the cell monolayer. 
 
 
Table 2: PCR reaction composition and conditions for site-directed mutagenesis 
 
PCR reaction mix PCR conditions 
Reagent Quantity (µl) 
 
1) Initial denaturation: 95°C for 30 sec 
 
2) 18 cycles of 
  a) Denaturation: 95°C for 30 sec 
  b) Annealing: 55°C for 1 min 
  c) Extension: 68°C (1 min per kb) 
 
3) Final extension: 68°C for 10 min 
 
10x reaction buffer 5.0 
Template (HA-PLK1, 
100ng/µl ) 1.0 
Forward primer (10 µM) 
Reverse primer (10 µM) 
1.5 
1.5 
10 mM dNTP 1.0 
Pfu DNA polymerase (2.5 
U/µl) 1.0 
Distilled water Up to 50.0 





Table 3: Primers used in cloning* 
 






























































2.4 Cell lysate preparation 
Total cell extract was prepared with either Lasemmli sample buffer or RIPA buffer. 
Cells were collected by trypsinization or mechanic shake-off (mitotic cells), washed 
once with ice-cold PBS and directly lysed in Laemmli sample buffer (LSB, 62.5 mM 
Tris-HCl pH 6.8, 2.5% SDS, 10% glycerol, 0.01% bromophenol blue) with 
dithiothreitol (DTT, 100 mM). The final concentration of the cell lysate was around 
15 million cells/ml. The cell lysate was boiled at 100°C for 3 min and sonicated for 10 
times at 20% amplification power (Sonics VCX130, Newtown, CT, USA). For 
western blotting, about 3 x 105 cells (20 µl of total cell extract) were loaded into one 
well of a SDS-PAGE gel.  
 
The other method is that after collection and one wash with ice-cold PBS, cells were 
resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4, 0.1% SDS, 150 mM NaCl, 5 
mM EDTA, 1% NP-40, 0.5% sodium deoxycholate) supplemented with protease and 
phosphoatase inhibitors (2mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 
µg/ml aprotinin, 1 µg/ml pepstatin A, 1 mM Na3VO4, and 5 mM NaF), sonicated on 
ice for 10 times and incubated on ice for another 15 min followed by centrifugation at 
20,000 g for 15 min at 4°C. The supernatant was transferred to a new tube and stored 
at -80°C. The concentration of the cell lysate was determined by Bradford protein 
assay. For western blotting, a total of 30 mg protein was loaded into one well of a 
SDS-PAGE gel. 
 
For immunoprecipitation or co-immunoprecipitation (co-IP), cells were collected by 
trypsinization or mechanic shake-off (mitotic cells), washed once with ice-cold PBS 
and resuspended in mild lysis buffer (150 mM NaCl, 20mM Tris-HCl, pH 8.0, 1% 




Triton X-100) supplemented with protease and phosphatase inhibitors. The final 
concentration of the cell lysate was around 10-20 million cells/ml. The cell lysate was 
passed through a syringe connected with a 21G needle for 20 times to shear the 
genomic DNA and incubated on ice for 15 min followed by centrifugation at 20,000 
at 4°C g for 15 min. The supernatant was considered as low-speed lysate (LSL). LSL 
were further centrifuged at 95,000 rpm for 30 min with a TLA-100.3 rotor (Beckman) 
and the supernatant was considered as high-speed lysate (HSL). 15 µl of the each 
supernatant was mixed with 2x LSB/DTT and boiled at 100°C for 3 min serving as 
input. The remaining supernatant was stored at -80°C. 
 
 
2.5 Bradford protein assay 
To find a standard curve, 1 mg/ml bovine serum albumin (BSA) was sequentially 
diluted to 0.2, 0.1, 0.05, 0.025, 0.0125 mg/ml with ddH2O. Protein samples were 
diluted at 1:30 or 1:50 with ddH2O to ensure the protein concentrations after dilution 
fall into the linear range of the assay (0.0125 to 0.2 mg/ml). 10 µl of blank (ddH2O), 
BSA standards and the diluted protein samples were added into UV-transparent 96-
well plate in triplicates. Each well was quickly topped up with 200 µl of 1 x Bradford 
dye (Bio-Rad). After 10 min incubation at RT, the absorbance of each sample at 595 
nm was measured using a UV-visible spectrophotometer (ULTRA-384, Tecan). The 
standard curve was determined in the form of the equation “y = mx + b”, where y = 
absorbance and x = BSA concentration. Concentrations of the protein samples were 
calculated using the generated equation based on their measured absorbance. 





2.6 Immunoprecipitation and western blotting 
Supernatant collected from cells lysed in mild lysis buffer (10-20 million cell/ml) was 
thawed at 4°C with gentle rotation for 20 min, followed by pre-cleared step with 10 µl 
TrueBlot Anti-Mouse Ig IP Beads (00-8811-25, Rockland) or TrueBlot Anti-Rabbit Ig 
IP Beads (00-8800-25, Rockland) for 1 h at 4°C with gentle rotation to remove non-
specific binding. After removal of the beads, 200 µl (IP for exogenous overexpression 
samples) or 600 µl (IP for the endogenous protein) of the lysate was incubated with 1-
2 µg of normal anti-mouse/rabbit IgG or 1-2 µg of primary antibody: rabbit anti-
MLL5-8009 antibody (in-house produced anti-MLL5 rabbit polyclonal antibody, 
which recognizes peptide sequence: 1155-CVSLLEYRKRQREAR-1169), mouse 
anti-γ-tubulin antibody (T5342, Sigma-Aldrich), mouse anti-FLAG antibody (F1804, 
Sigma-Aldrich) or mouse anti-HA antibody (H9658, Sigma-Aldrich) at 4°C for 3 h 
with gentle rotation. After the lysate-antibody mixture was incubated with 10 µl 
TrueBlot Anti-Mouse or Anti-Rabbit Ig IP Beads for another 1 h with gentle rotation, 
the immune complexes were spun down at 10,000 g for 1 min and washed with ice-
cold mild lysis buffer for three times. The proteins bound to the beads were eluted 
with 30 µl of 1.5 x LSB/DTT and boiled at 100°C for 5 min. After centrifugation at 
13,000 g for 1 min to separate the eluates from the beads, the supernatant was 
transferred to a fresh tube and stored at -20°C for western blotting analysis.  
 
Samples were resolved on SDS-PAGE gel of 6%-15% and run for the desired length 
of time until the dye front migrated out of the gel normally at 100 V for 20 min and 
120 V for another 70 min in SDS-PAGE running buffer (25 mM Tris base, 192 mM 
glycine, 0.1% SDS). Proteins in the SDS-PAGE gel were transferred onto a PVDF 
membrane at 70 mA for 2 h in transfer buffer (protein MW < 150 kDa: 25 mM Tris 




base, 192 mM glycine, 20% (v/v) methanol; protein MW > 150 kDa: 25 mM Tris 
base, 192 mM glycine, 20% (v/v) methanol, 0.05% SDS). The PVDF membrane had 
been activated by methanol for 1 min and equilibrated by transfer buffer subsequently. 
After transfection, the PVDF membrane was blocked with 5% skim milk in TBS (20 
mM Tris, 500 mM NaCl, 2.5 mM KCl) at 50 °C for 30 min and at RT for another 30 
min. The PVDF membrane was then incubated with primary antibody diluted in 
blocking buffer overnight at 4 °C and washed with 0.05% Triton X-100 in TBS for 1 
h, 5 min per wash (for MLL5) or with 0.05% Tween-20 in TBS for 30 min, 5 min per 
wash (for all other antibodies) before incubated with secondary antibody diluted in 
blocking buffer for 1.5 h at RT. After wash as above, substrate: Western lighting plus 
ECL (NEL104001EA, PerkinElmer) or Lumigen ECL Ultra (TMA-6, Beckman) was 
added onto the membrane. Signal was detected by x-ray film (Konica Minolta) in the 
dark room. 
 
2.7 GST protein expression and purification 
pGEX-GST or pGEX-GST-MLL5-CD4 was transformed to E. coli (BL21). Overnight 
bacterial culture from single colony was diluted at 1:100 to OD600 = 0.05 with LB 
(10% Bacto-tryptone 5% yeast extract, 10% NaCl, pH 7.5) containing 100 µl/ml 
ampicillin and 1% glucose. After incubation for 1-2 h with vigorous shaking at 200 
rpm to reach OD600 = 0.5, the expression of GST-MLL5-CD4 was induced with 0.1 
mM isopropyl 1-thio-β-D-galactopyranoside (IPTG). The bacterial culture was 
incubated for another 3 h at 30°C with shaking and subsequently spun down at 4000 
g. The pellet was resuspended in 10 ml of lysis buffer (100 mM NaCl, 50 mM Tris, 
1% Triton-X 100, pH 8.0) supplemented with protease inhibitor cocktail for bacteria 
(P8465, Sigma-Aldrich) and sonicated on ice for 15 min at 5 sec on and 25 sec off 





(Vibra-Cell, Sonics & Materials, Inc.). After centrifugation at 13,000 g for 15 min at 
4°C, the supernatant was incubated with 1 ml Glutathione SepharoseTM 4 Fast Flow 
beads (17-5132-01, GE Healthcare) with gentle rotation at 4°C for 2 h. The immune 
complexes were spun down at 1,000 g for 3 min and washed with lysis buffer for 
three times. The protein bound to the beads was eluted twice with 500 µl Glutathione 
elution buffer (50 mM Tris-HCl, 10mM Reduced Glutathione (GSH), pH 8.0) at RT 
for 15 min with gentle rotation. The concentration of purified GST-MLL5-CD4 was 
determined by Bradford protein assay (final yield: 1-2 mg/ml). 
 
2.8 In vitro kinase assay and mass spectrometry 
The In vitro kinase assay was performed in 20 µl reaction volume at 30°C for 30 min 
containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.1 mg/ml BSA, 250 µM DTT, 
0.1 mM ATP, 0.1 mM EDTA, 1 mM Na3VO4, 10 mM β-glycero phosphate, 10 µCi [γ-
32P] ATP (NEG502A250UC, PerkinElmer), 10 units of active PLK1, and 4 µg of 
casein (V2841, Promega), GST or GST-MLL5-CD4 purified above. Casein served as 
a positive control and 100 nM BI2536 (S1109, Selleck chemicals) was used as an 
inhibitor of PLK1. The reaction was terminated by adding 20 µl of 2 x LSB/DTT and 
boiling at 100°C for 3 min. The reaction mixture was resolved on a 10% SDS-PAGE 
gel and visualized by autoradiography or by commassie brilliant blue (CBB) staining 
as loading control.  
 
For mass spectrometry (MS), kinase assay products were resolved on a 10% SDS-
PAGE and stained by CBB. Protein bands of MLL5-CD4 were excised from the gel 
and analysed by MS using a 5600 TripleTOF analyser (QqTOF; AB SCIEX) at The 
Protein and Proteomics Centre, Department of Biological Sciences, National 




University of Singapore. Phosphorylation identification was performed with 
ProteinPilot™ Software 4.2 (AB SCIEX). 
 
2.9 Isolation of centrosomes 
About 1.5 × 108 exponentially growing U2OS cells were harvested and resuspended 
in complete medium containing 10 µg/ml nocodazole and 5 µg/ml cytochalasin B 
(C2743, Sigma-Aldrich) for 90 min. Cells were washed with ice-cold PBS and 8% 
sucrose in 0.1 × PBS and then lysed in hypotonic lysis buffer (1 mM Tris, pH 8.0, 
0.5% NP-40, 8 mM 2-mercaptoethanol and protease inhibitors) for 20 min on ice. The 
cell lysates were centrifuged at 1,800 g for 3 min and the supernatants containing 
centrosomes were applied onto 2 ml of 20% ficoll cushion (F4375, Sigma-Aldrich) 
followed by centrifugation at 30,000 g for 45 min in an Optima L-90K ultracentrifuge 
(Beckman Coulter) equipped with SW-28 rotor. 6 ml of liquid just above the ficoll 
cushion was pooled onto a 50 ml polypropylene tube containing a discontinuous 
(70%, 50%, and 40%) sucrose gradient. After centrifugation at 140,000 g for 90 min 
at 4°C, fractions of 0.5 ml were collected from the top using a pipette for subsequent 
western blotting analysis (Reber, 2011). 150 µl of 100% (w/v) TCA stock was added 
into 500 µl centrosome fractions followed by 10 min incubation on ice. Samples were 
centrifuged at 20,000 g for 5 min and the supernatant was removed. Pellets were 
washed by 200 µl ice-cold acetone and spun down for three times. After drying at 
95°C for 5 min, pellets were resuspended in 30 µl 2 x LSB/DTT, sonicated for 10 
times and stored at -20°C. 
 
 





2.10 RNA extraction, cDNA synthesis and real-time PCR (qPCR) 
Approximate 0.5 million cells were collected by trypsinization and spun down at 200 
g for 3 min at 4°C. The cell pellet was homogenized in 500 µl TRIzol reagent 
(#155967-026, Invitrogen) for 5 min at RT followed by addition of 100 µl chloroform. 
After vigorous votex for 15 sec, the mixture was incubated for 5 min at RT and 
centrifuged at 10,000 g for 15 min at 4 °C. The upper aqueous phase (~200 µl) was 
transferred to a fresh tube and 200 µl isopropanol was added. After centrifugation at 
10,000 g for 10 min at 4°C, the RNA pellet was washed with 500 µl 75% ethanol, air-
dried for 5 min and dissolved in 15 µl nuclease free water (#AM9939, Ambion). The 
RNA concentration was measured by a spectrophotometer (DS-11, DeNovix). For 
DNase treatment, 1 µg of RNA and 1 µl of DNase I topped up to 10 µl with water 
were incubated at 37 °C for 15 min and 65°C for 10 min. DNase I-treated RNA was 
converted to cDNA using the iScriptTM cDNA synthesis kit (170-8890, Bio-Rad). 
Details of the reaction conditions were listed in Table 4. The qRT-PCR reaction was 
performed in an iQ5 Multicolor Real-Time PCR machine (Bio-Rad) using the iTaqTM 
universal SYBR® green supermix (172-5120, Bio-Rad) according to the 
manufacturer’s instructions. Details of the qPCR conditions are listed in Table 5. 
Primers used for MLL5: sense 5’-CCACCACAAAAGAAAAAGGTTTCT C-3’ and 
antisense 5’-GTGTTGGTAAAGGTAGGCTAGC-3’. Primers used for GAPDH:  









Table 4: cDNA synthesis conditions 
cDNA reaction mix 
cDNA conditions 
Reagent Quantity (µl) 
5x iScript reaction mix 4 1) 25°C for 5 min  
2) 42°C for 30 min 
3) 85°C for 5 min 
4) Hold at 4°C  
iScript reverse transcriptase 1 
RNA template with DNase I 10 




Table 5: qPCR reaction mixture and conditions 
qPCR reaction mix in triplicates 
qPCR conditions 
Reagent Quantity (µl) 
iTaqTM universal SYBR® 
green supermix (2x) 25 1) Initial denaturation: 95°C for 30 sec 
2) Amplification (40 cycles) 
a. Denaturation: 95°C for 15 sec 
b. Annealing/Extension and plate 
read: 60°C for 30 sec 
3) Melt curve analysis: 65-95°C, 0.5°C 
increments at 3 sec/step 
Forward Primer (10 µM) 1.5 
Reverse Primer (10 µM) 1.5 
cDNA  1.5 




2.11 Immunofluorescence microscopy 
Cells grown on poly-D-lysine (1mg/ml) (Sigma, Cat No. 6403) coated coverslips 
were fixed with -20°C methanol for 10 min and rehydrated with 1x PBS. After 
permeabilization with 0.5% Triton X-100 in PBS for 5 min, the fixed cells were 
blocked in 5% bovine serum albumin (BSA) in PBS at RT for 2 h and subsequently 
incubated with primary antibodies diluted in the blocking buffer at 4°C overnight. 
Samples were washed with 0.05% Tween-20 in PBS for three times and incubated 
with secondary antibodies conjugated with Alexa Fluor 488 (green) or 568/594 (red) 





(Life Technologies) for 1.5 h. Unbound secondary antibodies were washed off with 
0.05% Tween-20 in PBS for three times and cellular DNA was counterstained with 
0.5 µg/ml of 4, 6-diamidino-2-phenylindole, dihydrochloride (DAPI, D1306, Life 
Technologies) at room temperature for 5 min. The samples were mounted with 
FluorSave reagent (#345789, Merck) to preserve fluorescence. Images were acquired 
using Olympus IX81 microscope equipped with a 100 × Plan Achromat oil immersion 
objective (NA 1.25) and a cooled charge-coupled device camera (QImaging). Images 
were analysed using QEDInVitroTM Version 3.2.2 and Image-Pro Plus 6.2 software 
(MediaCybernetics). 
 
2.12 Confocal microscopy 
Samples were prepared as in 2.11. Images were obtained using a confocal 
fluorescence microscope FV 1000 (Olympus) equipped with a 100 × Plan Achromat 
oil immersion objective (NA 1.25) or LSM 700/LSM 710 (Carl Zeiss) equipped with 
a 63× Plan Apochromat oil immersion objective (NA 1.4). For one mitotic cell, a 
stack of images in the Z-direction with optimized step size corresponding to the 
pinhole value was obtained. Images were analysed and exported after maximum 
intensity projection by Imaris 7.2.3 software (Bitplane, Zurich, Switzerland), ZEN 
2011 software (Carl Zeiss), or Image-Pro Plus software (MediaCybernetics). For 
three-dimensional reconstructions, deconvoluted confocal Z-stacks were rendered in 
three dimensions using Imaris 7.2.3.  
 
2.13 Time-lapse microscopy 
U2OS cells stably expressing GFP-tubulin were cultured on glass-bottom 35-mm 




culture dishes (World Precision Instruments) and assembled in a stage top incubator 
supplemented with 5% CO2. Sequences of images were acquired every 1 min for 30 
min using an inverted fluorescence microscope (Olympus) equipped with a 100 × 
Plan Achromat oil immersion objective (NA 1.25) and a cooled charge-coupled device 
camera (QImaging). Images were analysed using Image-Pro Plus software. 
 
2.14 Microtubule regrowth assay 
After transfection of NC- or MLL5-siRNA for 24 h, U2OS cells were synchronized to 
prometaphase by 100 ng/ml nocodazole for 16 h. Mitotic cells were collected by 
mechanic shake-off, resuspended in fresh medium containing 20 µM MG132. After 
1.5 h incubation, the cells were spun down at 200 g for 3 min, resuspended in ice-cold 
medium and incubated on ice for 30 min to depolymerize microtubule. Subsequently, 
the cells were centrifuged again and transferred into 35-mm culture dishes with poly-
D-lysine coated coverslips containing 37°C complete medium and 20 µM MG132. 
After 1.5 h incubation, immunofluorescence was performed as described in 2.11. 
 
2.15 Short hairpin RNA lentivirus production and transduction 
MLL5 specific shRNA (sense-5’-CCGGATGCTGAGAGAACAGTTTGAACTCGA 
GTTCAAACTGTTCTCTCAGCATTTTTTG, antisense-5’-AATTCAAAAAATGC 
TGAGAGAACAGTTTGAACTCGAGTTCAAACTGTTCTCTCAGCAT, targeting 
nucleotide position at 1556 from the transcription starting point) and scramble shRNA 
(sense-5’-CCGGTTCTCCGAACGTGTCACGTGACTCGAGTCACGTCACACGTT 
CGGAGAATTTTTG, antisense-5’-AATTCAAAAATTCTCCGAACGTGTCACGT 
GACTCGAGTCACGTCACACGTTCGGAGAA) were synthesized by 1st BASE 





(Singapore). They were annealed and cloned into the pLKO.1 vector. For recombinant 
lentivirus production, 293FT cells were co-transfected with 6 µg of targeting construct 
pLKO.1-NCshRNA or pLKO.1-MLL5shRNA, 5 µg of packaging construct pCMV-
dR8.91 and 2.5 µg of envelope plasmid PMD.G by using calcium phosphate 
transfection method for 48 h. The lentivirus containing medium was harvested and 
filtered through 0.45 µm filter (WAKI 2053-025). For cell transduction, the virus-
containing cell supernatant was diluted 1:1 in DMEM complete medium and added 
into U2OS cell. After 24 h incubation, cells were synchronized to mitosis for further 
experiments. All the lentiviral vectors were kind gifts from Academia Sinica, Taiwan. 
 
2.16 Statistical analysis 
All data shown in the results represent the mean value of three independent 
experiments. Error bars represent the standard error of mean (s.e.m). P-values were 
obtained by t test and represent a comparison of all cells analysed in the indicated cell 
populations. All statistical analyses were carried out using IBM SPSS Statistics 19. 




Table 6: Antibodies used in western blotting, immunofluorescence and immunoprecipitation 
Antibodies or Beads Manufacturer Catalogue No. Dilution Factor IF IP WB 
Aurora A Cell Signalling #4178P 1:100  1:1000 
Centrin 2 Santa Cruz sc-27793-R 1:100   
Cyclin B1 Santa Cruz sc-245   1:500 
CREST ImmunoVision HCT-0100 1:100   
FLAG Sigma-Aldrich F1804 1:1000 2 µg 1:1000 
GAPDH Santa Cruz sc-25778   1:1000 
HA Santa Cruz sc-805 1:100  1:1000 
HA Sigma-Aldrich H9658  2 µg  
MLL5 In-house purified 8009 1:100 2 µg 1:5000 
MLL5 (C-20) Santa Cruz sc-18214 1:100   
MLL5 (N-20) Santa Cruz sc-68636 1:100   
Pericentrin Abcam ab4448 1:1000   
PLK1 Santa Cruz sc-17783 1:100  1:500 
IF: immunofluorescence IP: immunoprecipitation WB: western blotting 





Antibodies or Beads Manufacturer Catalogue No. 
Dilution Factor 
IF IP WB 
α-tubulin Sigma-Aldrich T9026 1:3000  1:2000 
γ-tubulin Sigma-Aldrich T5342 1:1000 2 µg 1:2000 
γ-tubulin Sigma-Aldrich T3559 1:3000   
Goat anti-mouse, HRP conjugate Life Technologies 62-6520   1:10000 
Goat anti-rabbit, HRP conjugate Life Technologies 65-6120   1:10000 
Goat anti-mouse F(ab’)2 HRP conjugate Pierce 31166   1:5000 
Alexa Fluor ® 488 goat anti-mouse Invitrogen A11001 1:200   
Alexa Fluor ® 488 chicken anti-rabbit Invitrogen A11008 1:200   
Alexa Fluor ® 568 goat anti-mouse Invitrogen A11031 1:200   
Alexa Fluor ® 568 goat anti-rabbit Invitrogen A11011 1:200   
Alexa Fluor ® 594 goat anti-human Invitrogen A11014 1:200   
Normal mouse IgG Santa Cruz sc-2025  2 µg  
Normal rabbit IgG Santa Cruz sc-2027  2 µg  
Glutathione SepharoseTM 4 Fast Flow GE Healthcare 17-5132-01  1 ml  
TrueBlot® Anti-Mouse Ig IP Beads Rockland 00-8811-25  10 µl  
TrueBlot® Anti-Rabbit Ig IP Beads Rockland 00-8800-25  10 µl  




CHAPTER 3 – RESULTS 
 
 
As described earlier, MLL5 is a potential tumor suppressor gene regulating cell cycle 
progression. Moreover, MLL5 maintains genomic integrity by stabilizing the 
chromosomal passenger complex (CPC) at the kinetochore. Knockdown of MLL5 
caused degradation of CPC, resulting in chromosome misalignment. However, the 
restoration of CPC level in MLL5-KD cells only corrected the bipolar misalignment 
but not the multipolar misalignment, suggesting a potential CPC-independent role of 
MLL5 in spindle pole regulation (Liu et al., 2012). Furthermore, the subcellular 
localization of endogenous MLL5 other than nuclear localization has not been 
comprehensively studied. Here, we further identified MLL5 as a novel centrosome 
component and explored the function of MLL5 in centrosome regulation, especially 
the maintenance of spindle bipolarity during mitosis. 
 
3.1 MLL5 is a centrosomal protein 
 
To investigate MLL5 subcellular localization at different stages of a cell cycle, we 
first stained endogenous MLL5 in U2OS cells with in-house purified rabbit 
polyclonol antibody-8009. Cells at different phases were searched manually under the 
microscope. In line with previous finding, the endogenous MLL5 localized to the 
nucleus in interphase and delocalized from chromatin to cytoplasm from metaphase to 
cytokinesis. Moreover, MLL5 colocalized with γ-tubulin, a centrosome marker, 
throughout the cell cycle, indicating the presence of MLL5 at the centrosome (Figure 





3.1). To confirm the centrosomal localization of MLL5, two commercial anti-MLL5 
antibodies, which detected different regions of MLL5, were used in 
immunofluorescent staining. Consistently, the endogenous MLL5 localized to the two 
spindle poles represented by γ-tubulin at metaphase (Figure 3.2). Taken together, 
besides nuclear localization in interphase, MLL5 also localized to the centrosome 
regardless of cell cycle progression. This suggests a potential role of MLL5 in the 
regulation of centrosome and spindle pole during mitosis.  











Figure 3.1 MLL5 localizes to the centrosome throughout a cell cycle. U2OS cells 
at different phases of a cell cycle were immunostained by rabbit anti-MLL5-8009 
antibody and mouse anti-γ-tubulin antibody. DNA was counterstained with DAPI. γ-
tubulin serves as a centrosome marker. The scale bars represent 10 µm. Insets show 



















Figure 3.2 MLL5 localizes to the centrosome at metaphase. U2OS cells at 
metaphase were immunostained with two commercial goat anti-MLL5 antibodies and 
rabbit anti-pericentrin antibody. DNA was counterstained with DAPI. Pericentrin 
serves as a centrosome marker. The scale bars represent 10 µm.  





To further confirm that MLL5 is a component of the centrosome, we isolated 
centrosomes from U2OS cells using sucrose density-gradient ultracentrifugation. 
Exponentially growing cells lysed in hypotonic lysis buffer were centrifuged to 
remove unbroken cells and nucleus. The supernatant containing centrosomes were 
applied onto a ficoll cushion and centrifuged again. The 6 ml lysate just above the 
ficoll cushion containing concentrated centrosomes was applied onto a discontinous 
sucrose gradient (40%, 50% and 70%). After ultracentrifugation, the fractions 
collected from the top were subjected to western blotting. Results showed that after 
isolation, endogenous MLL5 and γ-tubulin were present in the same fractions: No. 24 
to No. 26 (Figure 3.3). This co-existence of MLL5 and γ-tubulin further demonstrates 
MLL5 as a centrosome component and implies a potential interaction between MLL5 









Figure 3.3 MLL5 and γ-tubulin are in the same fractions after centrosome 
isolation. U2OS cells treated with nocodazole and cytochalasin B were lysed with 
hypotonic lysis buffer. After removal of chromatin-bound proteins, centrosomes were 
concentrated onto a 20% ficoll cushion and then isolated by sucrose gradient 
centrifugation (40%, 50% and 70%). Fractions of concentrations ranging from 40% to 
60% were collected and detected by western blotting with rabbit anti-MLL5 and 








To verify such assumption, we carried out co-immunoprecipitation (co-IP) studies 
with U2OS cell lysates by pulling down endogenous MLL5 with anti-MLL5-8009 
antibody or rabbit IgG. The eluates were subjected to western blotting and the results 
are shown in Figure 3.4A. γ-tubulin could be co-immunoprecipitated with endogenous 
MLL5. Consistently, a reciprocal co-IP pulling down ectopically overexpressed 
FLAG-MLL5 in 293T cells with anti-γ-tubulin antibody or mouse IgG revealed that 
the ectopically overexpressed FLAG-MLL5 also interacted with γ-tubulin (Figure 
3.4B). Collectively, MLL5 not only co-exists with γ-tubulin in purified centrosomes, 
























Figure 3.4 Both endogenous MLL5 and exogenous FLAG-MLL5 interact with γ-
tubulin. (A) After synchronization to prometaphase by nocodazole treatment, U2OS 
cell lysates were immunoprecipitated with rabbit anti-MLL5-8009 antibody or rabbit 
IgG and detected by western blotting with rabbit anti-MLL5-8009 and mouse anti-γ-
tubulin antibodies. (B) 293T cells expressing FLAG-MLL5 were synchronized to 
prometaphase prior to immunoprecipitation with mouse anti-FLAG or mouse IgG. 








Since MLL5 is a relatively large protein with 1,858 amino acids, it is necessary to 
dissect it into smaller fragments and to narrow down the region responsible for the 
interaction with γ-tubulin. Therefore, three truncated MLL5 mutants were introduced, 
which were PHD/SET (PS) fragment, central domain (CD) fragment and C-terminal 
(CT) fragment. The three mutants still contained at least one nuclear localization 
signal, ensuring their correct subcellular localization (Deng et al., 2004; Liu et al., 
2010b). 293T cells overexpressing PS, CD or CT fragment of MLL5 were 
synchronized to mitosis by nocodazole treatment, lysed and immunoprecipitated by 
anti-γ-tubulin antibody or mouse IgG. Western blotting results demonstrated that only 
MLL5-CD but not MLL5-PS or MLL5-CT bound to γ-tubulin in mitosis (Figure 3.5). 
Strikingly, a slower migrating form of MLL5-CD could also be pulled downed by γ-
tubulin (Arrowhead in Figure 3.5B). MLL5 has been demonstrated to display slower 
gel mobility at G2/M phase and the slower migrating MLL5 could be converted to a 
faster form after phosphatase treatment, indicating that the slower gel mobility was 
due to phosphorylation (Liu et al., 2010b). Therefore, the slower migrating form of 
MLL5-CD here in Figure 3.5B implies that post-translational modifications (PTMs) 




























Figure 3.5 γ-tubulin binds to MLL5-CD and MLL5-CD with PTMs. (A) 
Schematic representation of truncated MLL5 mutants. PS, PHD/SET fragment; CD, 
central fragment; CT, C-terminal fragment. (B) 293T cells expressing FLAG-MLL5-
PS, FLAG-MLL5-CD, or FLAG-MLL5-CT were synchronized to mitosis by 16 h 
nocodazole treatment before immunoprecipitation with mouse anti-γ-tubulin antibody 
or mouse IgG. The IP eluates were subjected to western blotting probed by mouse 
anti-FLAG antibody or mouse anti-γ-tubulin antibody. Arrowhead indicates a slow 
migrating form of FLAG-MLL5-CD.   




3.2  Down-regulation of MLL5 induces aMTOC formation, resulting in spindle 
multipolarity 
 
To further explore the role of MLL5 in centrosome regulation, we carried out siRNA-
mediated knockdown of MLL5. U2OS cells transfected with either negative control 
(NC) or MLL5-specific siRNA for 48 h were subjected to western blotting, qPCR or 
immunofluorescence. Figure 3.6A revealed a drastic decrease in total protein level of 
endogenous MLL5 in MLL5-KD cells. The mRNA level of MLL5 in KD cells was 
also efficiently reduced to only 10% of that in the control cells (Figure 3.6B). 
Consistently, immunofluorescent staining for MLL5 and γ-tubulin showed a 
significant drop of MLL5 signal at the centrosome after the knockdown of MLL5 
(Figure 3.6C). Collectively, down-regulation of MLL5 via siRNA transfection was 



























Figure 3.6 Transfection of MLL5-siRNA efficiently down-regulates endogenous 
MLL5. (A) U2OS cells transfected with NC- or MLL5-siRNA for 48 h were 
harvested and subjected to western blotting. Endogenous MLL5 was detected by 
rabbitanti-MLL5-8009 antibody. α-tubulin serves as the loading control. (B) U2OS 
cells transfected with NC- or MLL5-siRNA for 48 h were harvested for qPCR. The 
CT value of MLL5 was normalized against GAPDH. (C) U2OS cells transfected with 
NC- or MLL5-siRNA for 48 h were fixed for immunofluorescence with rabbit anti-
MLL5-8009 antibody and mouse anti-γ-tubulin antibody. DNA was counterstained 
with DAPI. The scale bars represent 10 µm. 
 




3.2.1 Knockdown of MLL5 results in multipolar spindle with multiple 
centrosomes at metaphase 
Immunofluorescence against another centrosome marker, pericentrin and α-tubulin 
revealed that unlike NC-siRNA transfected cells displaying normal bipolar spindle, 
MLL5-KD cells showed multipolar spindle with multiple centrosomes (Figure 3.7A, 
Movie 3.7a (NC-siRNA) and 3.7b (MLL5-siRNA)). Quantitation of cells with 
multiple centrosomes (more than two pericentrin foci in one cell) revealed that the 
knockdown of MLL5 caused an approximate seven-fold increase in the population 
with more than two centrosomes compared to the control cells at metaphase (NC-
siRNA: 9.0%; MLL5-siRNA: 63.3%, p = 0.002, Figure 3.7B). Consistently, such 
centrosome abnormality along with multipolar spindle phenotype was also frequently 
observed after knockdown of MLL5 in normal diploid fibroblast WI-38 cells, 
embryonic kidney SV40-transformed 293T cells, and the cervical cancer HeLa cell 
line (Figures 3.8). These results indicate an indispensable role of MLL5 in the 
maintenance of spindle bipolarity. 





















Figure 3.7 Down-regulation of MLL5 causes multipolar spindle formation with 
multiple centrosomes at metaphase. (A) U2OS cells were transfected with NC- or 
MLL5-siRNA for 24 h followed by synchronization to prometaphase by 16 h 
nocodazole treatment. The cells were subsequently released into nocodazole-free 
complete medium containing MG132 for 1.5 h and fixed for immunofluorescent 
staining with rabbit anti-pericentrin antibody and mouse anti-α-tubulin antibody. DNA 
was counterstained with DAPI. The scale bars represent 10 µm. (B) Quantitation of 
cells with multiple centrosomes in A. Cell with more than two pericentrin foci was 
categorized as cell with > 2 centrosomes. 100 cells were counted manually per sample 
and the experiments were repeated three times. Error bars represent s.e.m. **, p = 
0.002. 





















Figure 3.8 Down-regulation of MLL5 causes multipolar spindle formation with multiple centrosomes at metaphase. Normal diploid 
fibroblast WI-38 cells, embryonic kidney SV40-transformed 293T cells, and the cervical cancer HeLa cell were transfected with NC- or MLL5-
siRNA for 24h followed by synchronization to prometaphase by 16 h nocodazole treatment. The cells were subsequently released into 
nocodazole-free complete medium containing MG132 for 1.5 h and fixed for immunofluorescent staining with rabbit anti-pericentrin antibody 
and mouse anti-α-tubulin antibody. DNA was counterstained with DAPI. The scale bars represent 10 µm. Cell with more than two pericentrin 
foci was categorized as cell with > 2 centrosomes. 100 cells were counted manually per sample. 
 
 





3.2.2 Knockdown of MLL5 does not cause multiple centrosomes at prometaphase 
Since multipolar spindle with multiple centrosomes can result from centriole over-
duplication at S phase, it is necessary to elucidate if the spindle multipolarity and 
centrosome abnormality in MLL5-KD cells at metaphase is due to centrosome 
amplification. To this end, U2OS cells transfected with NC- or MLL5-siRNA were 
arrested at prometaphase instead of metaphase by nocodazole treatment and subjected 
to immunofluorescence. Staining for the pericentriolar material (PCM) marker, γ-
tubulin, together with a centriole marker, centrin-2, demonstrated that multiple 
centrosomes were barely observed in MLL5-KD cells at prometaphase (NC: 4.0%; 
MLL5-siRNA: 3.3%). As shown in Figure 3.9, two γ-tubulin foci colocalized with 
two pairs of centriols were present in both control and MLL5-KD cells, indicating that 
the MLL5-KD cells underwent normal centrosome duplication and entered mitosis 
with two centrosomes, each containing a pair of centrioles.  





















Figure 3.9 Down-regulation of MLL5 does not lead to multiple centrosomes at 
prometaphase. (A) U2OS cells were transfected with NC- or MLL5-siRNA for 24 h 
followed by synchronization to prometaphase by 16 h nocodazole treatment. The cells 
were subsequently fixed for immunofluorescent staining with mouse anti-γ-tubulin 
antibody and rabbit anti-centrin-2 antibody. DNA was counterstained with DAPI. The 
scale bars represent 10 µm. (B) Quantitation of cells with multiple centrosomes in A. 
Cell with more than two γ-tubulin foci was categorized as cell with > 2 centrosomes. 
100 cells were counted manually per sample and the experiments were repeated three 
times.  





3.2.3 Multiple centrosomes in MLL5-KD cells are multiple PCM foci, not 
originating from centrioles 
The above findings reveal that the formation of supernumerary centrosomes occurred 
after prometaphase but before metaphase. In addition, the possibility of centrosome 
amplification due to centriole over-duplication at S phase in MLL5-KD cells is 
excluded. However, centriole disengagement during spindle formation is able to result 
in multiple centrosomes and spindle multipolarity. To examine whether there is 
centriole disengagement in MLL5-KD cells during mitosis, we co-stained centrin-2 
and γ-tubulin in U2OS cells, which were transfected with NC- or MLL5-siRNA and 
subsequently synchronized to metaphase. In line with previous results, MLL5-KD 
cells displayed multiple γ-tubulin foci. Yet, only two of these foci showed the 
presence of a pair of centrioles indicated by centrin-2 (Figure 3.10A). This indicates 
that centrioles remained intact in MLL5-KD cells and the multiple γ-tubulin foci did 
not originate from centriole. Further staining for different PCM proteins such as γ-
tubulin and pericentrin revealed that PCM proteins, on the other hand, always 
colocalized to each other, regardless of whether forming two foci in the control group 
or forming multiple foci in the MLL5-KD group (Figure 3.10B). Collectively, the 
supernumerary centrosomes in MLL5-KD cells at metaphase were centriole-
























Figure 3.10 Multiple centrosomes in MLL5-KD cells are centriole-independent. 
U2OS cells were transfected with NC- or MLL5-siRNA for 24 h followed by 
synchronization to prometaphase by 16 h nocodazole treatment. The cells were 
subsequently released into nocodazole-free complete medium containing MG132 for 
1.5 h and fixed for immunofluorescent staining with mouse anti-γ-tubulin antibody 
and rabbit anti-centrin-2 antibody in A or mouse anti-γ-tubulin antibody and rabbit 
anti-pericentrin antibody in B. DNA was counterstained with DAPI. The scale bars 
represent 10 µm.  





Since multipolar spindle with multiple centrosomes in MLL5-KD cells is due to 
supernumerary PCM foci, it is likely that PCM splits from the original two 
centrosomes under the microtubule pulling forces upon mitosis. To verify if 
microtubule dynamics plays a role in the formation of multiple PCM foci, we treated 
metaphase U2OS cells transfected with NC- or MLL5-siRNA with nocodazole for 30 
min to depolymerize microtubule and fixed the cells for immunofluorescence. 
Staining for PCM proteins such as γ-tubulin and pericentrin showed that the 
supernumerary PCM foci did not coalesce into two foci after microtubule 
depolymerization (Figure 3.11A). Further quantitation of cells with multiple PCM 
foci revealed a significantly higher percentage of cells with multiple centrosomes in 
MLL5-KD group than that in the control group (NC-siRNA: 3.7%; MLL5-siRNA: 
52.7%, p = 0.002) (Figure 3.11B). This suggests that the centrosome abnormalities 
occurring in MLL5-KD cells were microtubule-independent and were unlikely caused 
by PCM fragmentation. 
 
  























Figure 3.11 Multiple centrosomes in MLL5-KD cells at metaphase is 
microtubule-independent. (A) U2OS cells were transfected with NC- or MLL5-
siRNA for 24 h followed by synchronization to metaphase by 16 h nocodazole 
treatment and 1.5 h MG132 incubation. The cells were subsequently released from 
MG132 and incubated with nocodazole for another 30 min before fixation and stained 
with mouse anti-γ-tubulin antibody and rabbit anti-pericentrin antibody. DNA was 
counterstained with DAPI. The scale bars represent 10 µm. (B) Quantitation of cells 
with multiple centrosomes in A. Cell with more than two γ-tubulin/pericentrin foci 
was categorized as cell with > 2 centrosomes. 100 cells were counted manually per 
sample and the experiments were repeated three times. Error bars represent s.e.m. **, 
p = 0.002.  





3.2.4 Multiple centrosomes in MLL5-KD results from aMTOC formation  
The above findings have demonstrated that the spindle multipolarity in MLL5-KD 
cells is centriole-independent. Moreover, in spite of multiple PCM foci, PCM proteins 
do not spilt from the original two centrosomes. To understand how multipolar spindle 
is formed in MLL5-KD cells, we monitored live U2OS cells stably expressing GFP-
tagged α-tubulin by time-lapse microscopy after transfection of NC- or MLL5-siRNA. 
Unlike control cells, where the two centrosomes became microtubule-organizing 
centers (MTOCs) nucleating microtubules, MLL5-KD cells displayed extra MTOC 
formation in addition to the initial two centrosomes during microtubule nucleation 
(Figure 3.12 and Movies S3.12a (NC-siRNA), S3.12b (MLL5-siRNA)). Since extra 
MTOCs could not originate from centrioles (Figure 3.10A), those additional MTOCs 
were mislocalized PCM foci and thus acentrosomal MTOCs (aMTOCs). To further 
confirm that these PCM foci are functional, we carried out microtubule regrowth 
assay. U2OS cells transfected with NC- or MLL5-siRNA were treated with 
nocodazole for 16 h followed by MG132 incubation for another 1.5 h to achieve 
metaphase synchronization. The cells were subsequently washed with ice-cold 
medium and incubated on ice for 30 min to depolymerize microtubule before they 
were released into warm medium containing MG132 for another 1.5 h. The cells were 
then fixed for immunofluorescence. Only 3% of the control cells showed multipolar 
spindle with multiple centrosomes indicated by γ-tubulin. However, 69% of MLL5-
KD cells displayed spindle multipolarity (Figure 3.13), suggesting that the multiple 
centrosomes (PCM foci) in MLL5-KD cells were still able to organize mitotic spindle 
after microtubule depolymerisation by cold treatment. Taken together, knockdown of 
MLL5 induced formation of aMTOCs composed of PCM, which led to multipolar 
spindle at metaphase. 

















Figure 3.12 Additional MTOCs are formed in MLL5-KD cells. U2OS cells expressing GFP-α-tubulin were cultured on glass-bottom 35-mm 
culture dishes and transfected with NC- or MLL5-siRNA for 48 h. Sequences of images were acquired from prophase to metaphase. Frames 
taken at the indicated time points (hr:min) are shown. See Movie S3.12a (NC-siRNA) and Movie S3.12b (MLL5-siRNA). 
 
  




















Figure 3.13 Multipolar spindle is formed after release from cold treatment in 
MLL5-KD cells. (A) U2OS cells were transfected with NC- or MLL5-siRNA for 24 
h followed by synchronization to metaphase by 16 h nocodazole treatment and 1.5 h 
MG132 incubation. The cells were subsequently washed with ice-cold medium and 
incubated on ice for 30 min. The cells were then released into warm medium 
containing MG132 for 90 min and fixed for immunofluorescent staining with rabbit 
anti-γ-tubulin antibody and mouse anti-α-tubulin antibody. DNA was counterstained 
with DAPI. The scale bars represent 10 µm. (B) Quantitation of cells with multiple 
centrosomes in A. Cell with more than two γ-tubulin foci was categorized as cell 
with > 2 centrosomes. 100 cells were counted manually per sample.  




3.3 Knockdown of MLL5 leads to aberrant cytosolic aggregation of PLK1 
 
PLK1 plays a vital role in the centrosome cycle, especially centrosome maturation 
and has been demonstrated to control microtubule-based microtubule nucleation 
(Johmura et al., 2011). During mitosis, PLK1 is enriched at the centrosome and the 
kinetochore. Immunofluorescence showed that at metaphase PLK1 localized to the 
kinetochore overlapped by DAPI staining and, more importantly, colocalized with 
MLL5 at the centrosome (Figure 3.14A). This is in line with the centrosomal 
localization of both MLL5 and PLK1. Moreover, isolation of centrosomes from U2OS 
cell using sucrose density-gradient ultracentrifugation demonstrated that endogenous 
MLL5 and PLK1 were in the same fractions with γ-tubulin (Fraction No. 24 to No. 
26) (Figure 3.14B). These findings suggest a potential interaction between MLL5 and 
PLK1 at the centrosome. 
 
To answer whether knockdown of MLL5 has any effects on PLK1, we first examined 
the total protein level of PLK1 during mitosis. After transfection of NC- or MLL5-
siRNA for 24 h, U2OS cells were synchronized to mitosis by 16 h nocodazole 
treatment. Mitotic cells were collected by mechanic shake-off procedure and 
subjected to western blotting. As shown in Figure 3.15, siRNA-mediated knockdown 
of MLL5 efficiently reduced endogenous MLL5 level. However, total PLK1 protein 
level in mitosis was not affected. GAPDH serves as the loading control while cyclin 
B1 serves as the mitotic control.  


























Figure 3.14 PLK1 colocalizes with MLL5 at the centrosome. (A) U2OS cells were 
synchronized to metaphase by 16 h nocodazole treatment and 1.5 h MG132 
incubation and fixed for immunofluorescence with rabbit anti-MLL5-8009 antibody 
and mouse anti-PLK1 antibody. DNA was counterstained with DAPI. The scale bar 
represents 10 µm. (B) U2OS cells treated with nocodazole and cytochalasin B were 
lysed with hypotonic lysis buffer. After removal of unbroken cells and nucleus, the 
centrosomes were concentrated onto the 20% ficoll cushion and isolated by sucrose 
gradient centrifugation (40%, 50% and 70%). Fractions of concentrations ranging 
from 40% to 60% were collected and detected by western blotting with rabbit anti-
MLL5-8009 antibody, mouse anti-PLK1 antibody and mouse anti-γ-tubulin antibody. 
 
















Figure 3.15 Total PLK1 protein level is not affected by the knockdown of MLL5 
during mitosis. U2OS cells were transfected with NC- or MLL5-siRNA for 24 h and 
synchronized to prometaphase by 16 h nocodazole treatment. Mitotic cells were 
collected by shake-off and detected by rabbit anti-MLL5 antibody, mouse anti-PLK1 
antibody, mouse anti-cyclin B1 antibody and rabbit anti-GAPDH antibody. Cyclin B1 
serves as the mitotic control and GAPDH serves as the loading control. 
  





Although PLK1 expression level is not affected by the down-regulation of MLL5, we 
further investigated the subcellular localization of PLK1 in MLL5-KD cells. During 
early mitosis, PLK1 is recruited to the centrosome and the kinetochore. Thus, we 
stained for PLK1 either with the centrosome marker or with the kinetochore marker. 
Strikingly, down-regulation of MLL5 greatly increased the proportion of cells 
displaying aberrant cytosolic aggregates of PLK1, which localized to neither the 
centrosome indicated by pericentrin nor the kinetochore indicated by human CREST 
(arrowheads in Figure 3.16A-B). The proportion of cells with mislocalized PLK1 
aggregates were quantified and showed in Figure 3.16C. An increase from 18.0% to 
68.3% was observed after the knockdown of MLL5 (p = 0.005). These results suggest 
an indispensable role of MLL5 in the prevention of PLK1 mislocalization.  
 
In MLL5-KD cells, PLK1 seemed to dissociate from the centrosome but not the 
kinetochore localization (Figure 3.16A). To substantiate this, we quantified the 
centrosomal signal of PLK1 in both control and MLL5-KD cells. U2OS cells 
synchronized to prometaphase after siRNA transfection were fixed and subjected to 
immunofluorescence. Unlike control cells, where centrosomal PLK1 signal (green) 
merged with pericentrin signal (red) becoming yellow color, MLL5-KD cells showed 
dominant red color of pericentrin after merging with PLK1, indicating that PLK1 
signal was drastically lower after the knockdown of MLL5 (Figure 3.17A). 
Quantitation of PLK1 centrosomal signal further confirmed the significant decrease in 
the MLL5-KD cells compared to the control cells (Figure 3.17B). Considering that 
PLK1 formed cytosolic aggregates after MLL5 knockdown, we postulate that the 
aberrant cytosolic aggregation of PLK1 impaired PLK1 incorporation to the 
centrosome and thus caused the partial dissociation of PLK1 from the centrosome. 
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Figure 3.16 PLK1 forms aberrant cytosolic aggregates at prometaphase after down-regulation of MLL5. (A-B) U2OS cells were 
transfected with NC- or MLL5-siRNA for 24 h and were subsequently synchronized to prometaphase by 16 h nocodazole treatment. The cells 
were immunostained with mouse anti-PLK1 antibody and rabbit anti-pericentrin antibody or human anti-CREST antibody. DNA was 
counterstained with DAPI. Arrowhead indicates PLK1 aggregate. The scale bars represent 10 µm. (C) Quantitation of cells with PLK1 
aggregates at prometaphase in A. The experiments were repeated three times (n = 100 cells per sample). Error bars represent s.e.m. **, p = 
0.005. 





















Figure 3.17 PLK1 partially dissociates from the centrosome in MLL5-KD cells at 
prometaphase. (A) U2OS cells were transfected with NC- or MLL5-siRNA for 24 h 
and were subsequently synchronized to prometaphase by 16 h nocodazole treatment. 
The cells were immunostained with mouse anti-PLK1 antibody and rabbit anti-γ-
tubulin antibody. DNA was counterstained with DAPI. The scale bars represent 10 
µm. (B) Quantitation of centrosomal PLK1 signal at prometaphase in A (a.u., 
arbitrary unit). Thirty cells were captured per sample manually and mean pixel 
intensity of PLK1 was computed. ***, p < 0.001.  




The above findings demonstrate that after knockdown of MLL5, PLK1 partially 
dissociated from the centrosome and formed mislocalized aggregates at neither the 
centrosome nor the kinetochore at prometaphase. It is intriguing to further elucidate if 
these PLK1 aggregates could still be observed after cells proceed from prometaphase 
to metaphase and if they are related to the multipolar spindle formation with multiple 
centrosomes observed previously. For this purpose, we performed immunofluorescent 
staining with cells at metaphase. NC- or MLL5-siRNA transfected U2OS cells were 
arrested at prometaphase first by 16 h nocodazole treatment and further synchronized 
to metaphase by 1.5 h MG132 incubation. The cells were then fixed and 
immunostained for PLK1 and pericentrin. In control cells, PLK1 localized to the two 
centrosomes as well as the very well aligned kinetochores overlapped by DAPI 
staining (Figure 3.18, upper panel, Movie 3.18a (NC-siRNA)). Consistent with 
previous findings, multiple centrosomes (pericentrin foci) were observed in MLL5-
KD cells. Moreover, PLK1 localized to each of the pericentrin foci (arrows in Figure 
3.18, middle and lower panels, Movie 3.18b and 3.19c (MLL5-siRNA)). This implies 
an involvement of PLK1 aggregates in the establishment of aMTOCs that became 
acentrosomal spindle poles. However, not all the PLK1 aggregates resulted in the 
formation of new spindle poles as the MLL5-KD cells with multiple centrosomes still 
had cytosolic aggregates of PLK1 that neither colocalized with pericentrin nor 
overlapped with DAPI staining (PLK1 kinetochore localization) (arrowheads in 
Figure 3.18, middle and lower panels), indicating that some of the PLK1 aggregates 
were incapable of turning itself into aMTOC probably due to their insufficient kinase 
activity or binding capability. 
 
 






















Figure 3.18 PLK1 localizes to all the multiple centrosomes in MLL5-KD cells. 
U2OS cells were transfected with NC- or MLL5-siRNA for 24 h and synchronized to 
metaphase by 16 h nocodazole treatment and 1.5 h MG132 incubation. The cells were 
immunostained with mouse anti-PLK1 antibody and rabbit anti-pericentrin antibody. 
DNA was counterstained with DAPI. Arrow indicates the colocalization of PLK1 and 
pericentrin. Arrowhead indicates PLK1 cytosolic aggregates not colocalizing with 








Upon knockdown of MLL5, PLK1 formed cytosolic aggregates at both prometaphase 
and metaphase (Figure 3.16 and Figure 3.18). Moreover, the centrosomal localization 
of PLK1 was impaired at prometaphase (Figure 3.17). Next, we examined PLK1 
centrosomal signal at metaphase to access if the dissociation of PLK1 centrosomal 
localization of PLK1 could remain till metaphase. Since centriole number is not 
affected by the knockdown of MLL5 in spite of multiple PCM foci at metaphase 
(Figure 3.10A), we co-stained PLK1 and the centriole marker, centrin-2, to 
distinguish PLK1 signal from the original two centrosomes in MLL5-KD cells at 
metaphase. U2OS cells transfected with NC- or MLL5-siRNA were synchronized to 
metaphase by 16 h nocodazole treatment and 1.5 h MG132 incubation. In concert 
with the results in Figure 3.17A, signal from centriole-localized PLK1 was greatly 
lower in MLL5-KD cells compared to the control cells (Figure 3.19). Additionally, 
PLK1 cytosolic aggregates were present in the MLL5-KD cells. However, due to the 
lack of PCM marker such as pericentrin or γ-tubulin, these PLK1 aggregates were 
likely to be aMTOCs, which could not be distinguished here. Taken together, the 
down-regulation of MLL5 caused PLK1 to delocalize from the centrosome. 
  


















Figure 3.19 PLK1 dissociates from the centrosome in MLL5-KD cells at 
metaphase. U2OS cells were transfected with NC- or MLL5-siRNA for 24 h and 
subsequently synchronized to metaphase by 16 h nocodazole treatment and 1.5 h 
MG132 incubation. The cells were immunostained with mouse anti-PLK1 antibody 
and rabbit anti-centrin-2 antibody. DNA was counterstained with DAPI. The scale 
bars represent 10 µm. 
 
  




3.4 Cytosolic interaction between MLL5 and PLK1 is required for spindle 
bipolarity 
 
One possible explanation for PLK1 mislocalization (cytosolic aggregation and 
dissociation from the centrosome) in the MLL5-KD cells could be that centrosomal 
MLL5 is required for PLK1 recruitment to the centrosome. However, the observation 
that PLK1 still partially localized to the centrosome in the MLL5-KD cells argue 
against this hypothesis (Figure 3.17). Since MLL5 delocalizes from the nucleus to the 
cytoplasm but maintains its centrosomal localization during mitosis (Liu et al., 
2010b), it is plausible that cytosolic MLL5 plays a role in preventing PLK1 from 
mislocalization.  
 
To test this hypothesis, we first depleted centrosomal MLL5 by eliminating the 
centrosome. As described in the introduction, knockdown of PLK4 via siRNA 
transfection was able to eliminate the centrosome (Habedanck et al., 2005; Holland et 
al., 2012). U2OS cells were transfected with NC- or PLK4-siRNA for 48 h before 
synchronized to metaphase by nocodazole-MG132 treatment. The cells were then 
fixed and immunostained for MLL5 and γ-tubulin. Although the majority of PLK4-
siRNA-transfected U2OS cells were arrested at interphase, among those successfully 
synchronized to metaphase, 49% displayed one centrosome and 22% had no 
centrosomes (Figure 3.20A). Moreover, in the PLK4-depleted cells without any 
centrosome but forming acentrosomal spindle, centrosome-localized MLL5 was 
successfully eliminated (Figure 3.20B). 
  





















Figure 3.20 Knockdown of PLK4 eliminates the centrosome and centrosomal 
MLL5. (A) The percentage of cells with different numbers of the centrosome in 
control or PLK4-KD cells. U2OS cells were transfected with NC- or PLK4-siRNA for 
48 h before synchronization to metaphase by nocodazole-MG132 treatment. The cells 
were immunostained with anti-centrin-2 and anti-α-tubulin antibodies. Cells were 
counted manually for three times (n = 100 cells per sample). (B) Depletion of 
centrosomal MLL5. U2OS cells transfected with NC- or PLK4-siRNA were 
synchronized to metaphase and immunostained for MLL5 (green) and γ-tubulin (red). 
 
  




Interestingly, loss of centrosomal MLL5 in PLK4-KD cells did not result in a drastic 
increase in the cells with cytosolic PLK1 aggregates (Figure 3.21A, left panel; Figure 
3.21B, p > 0.05, NC-siRNA vs PLK4-siRNA). Moreover, the percentage of cells with 
multipolar spindle remained low in the centrosome-depleted cells (Figure 3.22A, left 
panel; Figure 3.22B, p > 0.05, NC-siRNA vs PLK4-siRNA). These results indicate 
that centrosomal MLL5 was not essential for keeping PLK1 in a non-aggregated form 
and not required for maintaining spindle bipolarity.  
 
Next, we depleted cytosolic MLL5 in these NC- or PLK4-siRNA-transfected U2OS 
cells and examined the effects on PLK1 aggregation and spindle bipolarity. To 
increase MLL5 knockdown efficiency in the centrosome-depleted cells, NC- or 
PLK4-siRNA-transfected cells were transduced with NC- or MLL5-shRNA by 
lentivirus infection for 24 h before synchronization to metaphase by nocodazole-
MG132 treatment. Both PLK4 and MLL5 were greatly down-regulated after 
siRNA/shRNA treatment (Figure 3.23). Strikingly, down-regulation of cytosolic 
MLL5 led to significantly elevated levels of cells displaying cytosolic PLK1 
aggregates in spite of the number of the centrosome (arrowhead in Figure 3.21A; 
Figure 3.21B, p < 0.001, NC-shRNA vs MLL5-shRNA). Furthermore, the percentage 
of cells with multipolar spindle became dramatically higher upon knockdown of 
cytosolic MLL5 (Figure 3.22, p < 0.001, NC-shRNA vs MLL5-shRNA). Taken 
together, cytosolic MLL5 rather than centrosomal MLL5 is required for the 
prevention of aberrant PLK1 aggregation and is crucial for the maintenance of bipolar 
spindle formation during mitosis. 




























Figure 3.21 Cytosolic interaction between MLL5 and PLK1 is essential for the prevention of PLK1 aggregation. (A) An increase in PLK1 
aggregates after down-regulation of cytosolic MLL5. U2OS cells were transfected with NC- or PLK4-siRNA for 24 h and further transduced 
with NC- or MLL5-shRNA through lentiviral infection for another 24 h. Cells were then synchronized to metaphase by nocodazole-MG132 
treatment and immunostained for PLK1 (red) and centrin-2 (green). Arrowhead indicates PLK1 aggregate. (B) Quantitation of cells with PLK1 
aggregates in A. The experiments were repeated three times (n = 50 cells per sample). Error bars represent s.e.m. 2*, 2 centrosomes. 1*, 1 
centrosome. 0*, 0 centrosome. ***, p < 0.001.














Figure 3.22 Cytosolic interaction between MLL5 and PLK1 is required for spindle bipolarity. (A) An increase in multipolar spindle after 
down-regulation of cytosolic MLL5. U2OS cells were introduced with NC- or PLK4-siRNA for 24 h and NC- or MLL5-shRNA for another 24 
h. Cells were then synchronized to metaphase immunostained for α-tubulin (red) and centrin-2 (green). Insets show high magnification (2.5x) 
images of centriole(s). (B) Quantitation of cells with monopolar, bipolar and multipolar spindle in A. The experiments were repeated three times 
(n = 50 cells per sample). 2*, 2 centrosomes. 1*, 1 centrosome. 0*, 0 centrosome. ***, p < 0.001. 

































Figure 3.23 Relative PLK4 and MLL5 mRNA levels after down-regulation of 
PLK4 and MLL5. U2OS cells were transfected with NC- or PLK4-siRNA for 24 h 
and transduced with NC- or MLL5-shRNA for another 24 h. Cells were then 
synchronized to mitosis and subjected to total RNA extraction and subsequent qRT-
PCR. Error bars represent s.e.m. ***, p < 0.001. The scale bars in A, D and F 
represent 10 µm. DNA in A, D and F was counterstained with DAPI (blue). Results in 
B and C are representative of at least three experimental repeats. 
  




Inhibition of PLK1 by BI2536 incubation at metaphase causes mitotic spindle 
collapse and PLK1 dissociation from the centrosome (Lenart et al., 2007). 
Consistently, metaphase cells treated with BI2536 became monopolar. Interestingly, 
PLK1 also formed mislocalized cytosolic aggregates (arrowhead in Figure 3.24A), 
which neither colocalized with pericentrin nor overlapped with DAPI staining. 
Intriguingly, endogenous MLL5 localized to those mislocalized aggregates of PLK1 
indicated by arrowhead in PLK1-inhibited cells besides its centrosomal localization at 
the center of the cell indicated by arrow (Figure 3.24B). This suggests a strong 
association between MLL5 and PLK1. 
 
Considering that MLL5 in the cytosol but not at the centrosome is essential for 
preventing PLK1 from aberrant cytosolic aggregation, we next verify if MLL5 
physically interacts with PLK1 in the cytosol. U2OS cells or 293T cells expressing 
FLAG-MLL5 and HA-PLK1 were synchronized to mitosis. Cell lysates were first 
centrifuged at 12,000 g and the collected supernatant were further subjected to 
ultracentrifugation (95,000 rpm, TLA100.3 rotor) to remove the remaining 
centrosome fragments. Co-IP was carried out in both low-speed lysate (LSL) 
containing centrosomes and high-speed lysate (HSL) lacking centrosomes 
(Gopalakrishnan et al., 2011; Wueseke et al., 2014). As shown in Figure 3.25A, 
endogenous PLK1 was co-immunoprecipitated with endogenous MLL5 not only in 
LSL but also in HSL, confirming the cytosolic interaction between MLL5 and PLK1. 
Likewise, HA-PLK1 could be pulled-down by FLAG-MLL5 in both LSL and HSL 
(Figure 3.25B). Collectively, MLL5 and PLK1 interact with each other in the cytosol 
at mitosis and such interaction prevents cytosolic aggregation of PLK1 as well as 
spindle multipolarity. 
  





















Figure 3.24 MLL5 localizes to PLK1 cytosolic aggregates in PLK1-inhibited 
cells. (A-B) U2OS cells arrested at metaphase by 16 h nocodazole treatment and 1.5 h 
MG132 incubation were treated with 100 nM BI2536 for 1.5 h. The cells were 
immunostained with mouse anti-PLK1 antibody and rabbit anti-pericentrin antibody 
or rabbit anti-MLL5-8009 antibody. DNA was counterstained with DAPI. The scale 
bars represent 10 µm.  



















Figure 3.25 MLL5 interacts with PLK1 in the cytosol at mitosis. (A) Cytosolic 
interaction between endogenous MLL5 and PLK1. Mitotic U2OS cell lysates were 
ultracentrifuged at 95,000 rpm with a TLA100.3 rotor after a low-speed centrifugation 
(12,000 g). Supernatants before (LSL) and after (HSL) ultracentrifugation were then 
immunoprecipitated with anti-MLL5 antibody or rabbit IgG and detected by western 
blotting with anti-MLL5 and anti-PLK1 antibodies. (B) Cytosolic interaction between 
FLAG-MLL5 and HA-PLK1. HSL and LSL of 293T cells co-expressing FLAG-
MLL5 and HA-PLK1 were immunoprecipitated with anti-FLAG antibody or mouse 
IgG and detected by western blotting with anti-FLAG and anti-HA antibodies.  
  





3.5 The PLK1 PBD interacts with the Thr887-Ser888-Thr889 motif on MLL5 
 
The presence of MLL5 in PLK1 cytosolic aggregates after inhibition of PLK1 implies 
a potential interaction between MLL5 and PLK1, which is independent of PLK1 
kinase activity (Figure 3.24). Moreover, MLL5 has been demonstrated to physically 
interact with PLK1 in the cytosol at mitosis (Figure 3.25).  
 
To further assess which part of MLL5 binds to PLK1, we carried out co-IP. Three 
truncated MLL5 mutants (PS, CD and CT) with FLAG-tag were overexpressed in 
293T cells with HA-tagged PLK1. After synchronization to mitosis by 16 h 
nocodazole treatment, the cells were lysed and immunoprecipitated by anti-HA 
antibody or mouse IgG. The IP products were subjected to western blotting and the 
results were shown in Figure 3.26. Similar to the interaction between MLL5 and γ-
tubulin, only the central domain of MLL5 bound to PLK1. Moreover, the slower-
migrating form of MLL5-CD, which is MLL5 with relatively more PTMs could also 
be pulled down by HA-PLK1, suggesting a potential function of the PTMs on MLL5 
in the interaction with PLK1.  
 
In line with previous results, removal of centrosome fragments by ultracentrifugation 
did not abrogate such binding. This indicates a cytosolic interaction between MLL5-
CD and PLK1 during mitosis (Figure 3.27). 
 
  











Figure 3.26 PLK1 binds to MLL5-CD. 293T cells expressing HA-PLK1 and FLAG-
MLL5-PS, FLAG-MLL5-CD, or FLAG-MLL5-CT were synchronized to mitosis by 
16 h nocodazole treatment before immunoprecipitation with mouse anti-HA antibody 
or mouse IgG. The IP eluates were subjected to western blotting probed by rabbit anti-






















Figure 3.27 MLL5-CD interacts with PLK1 in the cytosol. HSL and LSL of 293T 
cells expressing FLAG-MLL5-CD and HA-PLK1 were immunoprecipitated with anti-
HA antibody or mouse IgG and detected by western blotting with anti-FLAG and 
anti-HA antibodies. LSL, low-speed lysate. HSL, high-speed lysate. 
  





PLK1 binds to other proteins through its N-terminal polo-box domain and 
phosphorylates its substrates by the C-terminal kinase domain. To reveal which part(s) 
of PLK1 is responsible for the interaction with MLL5-CD, a kinase-dead HA-PLK1 
mutant (HA-PLK1-D194A substituting Asp-194 to alanine) and a polo-box domain-
mutated HA-PLK1 mutant (HA-PLK1-H538A-K540M converting His-538 to alanine 
and Lys-540 to methionine) were generated (Elia et al., 2003b). Overexpression of 
FLAG-MLL5-CD and HA-PLK1 or its mutant in mitotic 293T cells followed by IP 
with anti-HA antibody revealed that kinase-dead PLK1 still bound to both forms of 
MLL5-CD. However, PBD-mutated PLK1 lost its binding to the slower migrating 
form of MLL5-CD, suggesting that the PTMs on MLL5 is critical for the PLK1 PBD 











Figure 3.28 The PBD of PLK1 binds to the slower migrating form of MLL5-CD. 
293T cells expressing FLAG-MLL5-CD and HA-PLK1 or its mutant were 
synchronized to mitosis by 16 h nocodazole treatment before immunoprecipitation 
with mouse anti-HA antibody. The IP eluates were subjected to western blotting 
probed by rabbit anti-FLAG and rabbit anti-HA antibody. Arrow indicates a slower-
migrating form of FLAG-MLL5-CD. Arrowhead indicates a faster-migrating form of 
FLAG-MLL5-CD. 




The PBD of PLK1 preferably binds to serine or threonine, which is phosphorylated by 
a priming kinase (Elia et al., 2003a). Among all the pro-directed kinases identified so 
far, CDK1 is the most frequently reported one. Interestingly, MLL5 is phosphorylated 
by CDK1 on Thr-912 at the onset of mitosis (Liu et al., 2010). To figure out whether 
Thr-912 is the docking site for PLK1 PBD binding, we introduced a truncated mutant 
of the central domain of MLL5, MLL5-CD4 (Figure 3.29A), which displayed 
multiple slower-migrating forms during mitosis (Figure 3.29B, lower left panel), 
indicating multiple PTMs on MLL5. Additionally, MLL5-CD4-T912A mutant, which 
could not be phosphorylated by CDK1, was generated by converting Thr-912 to 
alanine. Both MLL5-CD4 and MLL5-CD4-T912A were overexpressed in 293T with 
HA-PLK1 or PBD-mutated HA-PLK1. After synchronization to mitosis by 
nocodazole treatment, the cells were lysed and immunoprecipitated with ant-HA 
antibody. Western blotting showed that the slowest migrating form of MLL5-CD4 
bound to the PBD of PLK1 (arrow in Figure 3.29B). This indicates that the PBD 
binding site on MLL5 is within CD4 fragment. However, the mutation of T912A did 
not abrogate such binding, since the slowest migrating form of MLL5-CD4-T912A 
still co-immunoprecipitated with HA-PLK1 but not with PBD mutated HA-PLK1 
(arrow in Figure 3.29B). This excludes the possibility that the CDK1 phosphorylation 























Figure 3.29 The PBD of PLK1 binds to the slowest migrating form of MLL5-
CD4 and MLL5-CD4-T912A. (A) Schematic representation of MLL5-CD4. (B) 
293T cells expressing FLAG-MLL5-CD4 or FLAG-MLL5-CD4-T912A and HA-
PLK1 or PBD-mutated HA-PLK1 were synchronized to mitosis by 16 h nocodazole 
treatment before immunoprecipitation with mouse anti-HA antibody. The IP eluates 
were subjected to western blotting probed by rabbit anti-FLAG antibody and rabbit 









To map the region of MLL5 responsible for the PLK1 PBD binding, we introduced 
another two truncated mutants of MLL5 smaller than CD4 fragment (Figure 3.30A). 
FLAG-tagged MLL5-CD6 or MLL5-CD9 was expressed in 293T cells with HA-
PLK1 or PBD-mutated HA-PLK1. After synchronization to mitosis, the cells were 
lysed and subjected to co-IP. Western blotting demonstrated that PLK1 interacts with 
the slowest migrating form of MLL5-CD6 and MLL5-CD9, while PBD-mutated 
PLK1 lost such bindings (Figure 3.30B). These results narrow down the region 






































Figure 3.30 The PBD of PLK1 binds to the slowest migrating form of MLL5-
CD6 and MLL5-CD9. (A) Schematic representation of truncated MLL5-CD 
mutants. (B) 293T cells expressing FLAG-MLL5-CD4 or FLAG-MLL5-CD6 and 
HA-PLK1 or PBD-mutated HA-PLK1 were synchronized to mitosis by 16 h 
nocodazole treatment before immunoprecipitation with mouse anti-HA antibody. The 
IP eluates were subjected to western blotting probed by rabbit anti-FLAG antibody 
and rabbit anti-HA antibody. Arrow indicates the slowest-migrating form of FLAG-
MLL5-CD6 or FLAG-MLL5-CD9.  




Next, we discovered five putative binding motifs on MLL5-CD9 according to the 
consensus-binding sequence for the PLK1 PBD interaction (Φ/P-Φ-Τ/Q/H/M-S-
pT/pS-P/X, where X is any amino acid residue and Φ is a hydrophobic residue). After 
construction of double or triple alanine mutants using MLL5-CD4 as the template, the 
mutants were co-expressed with HA-PLK1 in 293T cells synchronized to mitosis. The 
cell lysates were immunoprecipitated with anti-HA antibody and the IP eluates were 
subjected to western blotting. Among the five mutants, only MLL5-CD4-
TST887AAA triple alanine mutant displayed marked reduction in the interaction with 
the PLK1 PBD (arrow in Figure 3.31). All the other four mutants remained interaction 
comparable to wild-type MLL5-CD4. These results demonstrate an indispensable role 
of the Thr887-Ser888-Thr889 (TST887) motif in PLK1 PBD binding to MLL5.  
 
To further identify the specific site responsible for the PLK1 PBD binding, we 
dissected the triple alanine mutant into three single mutants: T887A, S888A and 
T889A. The mutants as well as the TST887AAA triple mutant were overexpressed 
with HA-PLK1 in 293T cells, which were subsequently synchronized to mitosis by 
nocodazole treatment. The cell lysates were immunoprecipitated by anti-HA antibody 
and the IP eluates were subjected to western blotting. Consistently, TST887AAA 
triple alanine mutant drastically lost its interaction with the PLK1 PBD (arrow in 
Figure 3.32). Moreover, the S888A mutant displayed the same loss of PBD binding 
just as the TST887 mutant, implying that Ser-888 is the most critical site in the 
TST887 motif. Beside the S888A mutant, the T889A mutant also showed significant 
reduction in binding to the PLK1 PBD. Nevertheless, the S887A mutant displayed 
least reduction.  











Figure 3.31 The PLK1 PBD loses binding to the slowest-migrating form of 
FLAG-MLL5-CD4-TST887AAA. 293T cells expressing FLAG-MLL5-CD4 or its 
mutant and HA-PLK1 were synchronized to mitosis by 16 h nocodazole treatment 
before immunoprecipitation with mouse anti-HA antibody. The IP eluates were 
subjected to western blotting probed by rabbit anti-FLAG antibody and rabbit anti-HA 









Figure 3.32 The PLK1 PBD loses binding to the slowest-migrating form of 
FLAG-MLL5-CD4-S888A. 293T cells expressing FLAG-MLL5-CD4 or its mutant 
and HA-PLK1 were synchronized to mitosis by 16 h nocodazole treatment before 
immunoprecipitation with mouse anti-HA antibody. The IP eluates were subjected to 
western blotting probed by rabbit anti-FLAG antibody and rabbit anti-HA antibody. 
Arrow indicates the slowest-migrating form of FLAG-MLL5-CD4 or its mutant.  




The PBD of PLK1 has been reported to preferably bind to phosphorylated serine or 
threonine (Elia et al., 2003a). To verify if phosphorylation of Ser-888 is required for 
the PLK1 PBD binding to MLL5, we constructed a phospho-mimicking mutant, 
MLL5-CD4-S888D and overexpressed FLAG-MLL5-CD4 or its mutant (S888D, 
S888A) together with HA-PLK1 in mitotic 293T cells. Co-IP using anti-HA antibody 
revealed that the mutation of serine to aspartic acid mimicking phosphorylation on 
Ser-888 also totally abrogated the interaction between MLL5 and PLK1 just as the 
S888A mutant did (Figure 3.33). Although phospho-mimicking mutation likely affect 
the overall conformation of the TST887 motif, it is possible that phosphorylation of 
MLL5 on Ser-888 is not required for the PLK1 PBD binding.  
 
We have demonstrated that the TST887 motif on MLL5 is indispensable for the PLK1 
PBD binding to MLL5. In addition, the CDK1 phosphorylation of MLL5 on Thr-912 
does not provide a docking site. Yet, it is possible that CDK1 or even PLK1 itself 
phosphorylates MLL5 on other site(s), which contributes to the PLK1 PBD binding to 
MLL5. To assess this possibility, we co-expressed MLL5-CD4 and HA-PLK1 or 
PBD-mutated HA-PLK1 in 293T cells, which were subsequently synchronized to 
mitosis and incubated with RO3306, the CDK1 inhibitor or with BI2536, the PLK1 
inhibitor for 1.5 h. The cell lysates were subjected to co-IP using anti-HA antibody. 
Although the inhibition of PLK1 did not impair the PLK1 PBD interaction with 
MLL5, the inhibition of CDK1 kinase activity significantly reduced such interaction 
(Figure 3.34). These results suggest an active role of CDK1 in the PLK1 binding to 
MLL5. However, MS detecting phosphorylation on GST-MLL5-CD4 after CDK1 in 
vitro kinase assay did not identify any phosphorylation other than T912 (data not 
shown). Thus, CDK1 may not phosphorylate MLL5 and provide a docking site for the 
PLK1 PBD binding, but activate a downstream target mediating the binding. 











Figure 3.33 The PLK1 PBD does not bind to FLAG-MLL5-S888D. 293T cells 
expressing FLAG-MLL5-CD4 or its mutant and HA-PLK1 were synchronized to 
mitosis by 16 h nocodazole treatment before immunoprecipitation with mouse anti-
HA antibody. The IP eluates were subjected to western blotting probed by rabbit anti-
FLAG antibody and rabbit anti-HA antibody. Arrowhead indicates the slowest-
















Figure 3.34 Inhibition of CDK1 by RO3306 abrogates the interaction between 
the PLK1 PBD and the slowest-migrating form of FLAG-MLL5-CD4. 293T cells 
expressing FLAG-MLL5-CD4 and HA-PLK1 or PBD mutated HA-PLK1 were 
synchronized to mitosis by 16 h nocodazole treatment followed by incubation with 
BI2536 or RO3306 for 1.5 h before immunoprecipitation with mouse anti-HA 
antibody. The IP eluates were subjected to western blotting probed by rabbit anti-
FLAG antibody and rabbit anti-HA antibody. Arrow indicates the slowest migrating 
form of FLAG-MLL5-CD4 or its mutant.  
  




3.6 PLK1 phosphorylates MLL5 on Ser-861 
 
PLK1 has been demonstrated to interact with the Thr887-Ser888-Thr889 motif on 
MLL5 through its PBD. In addition, MLL5 especially MLL5-CD4 displayed multiple 
slower-migrating forms, suggesting a number of PTMs added onto MLL5 upon 
mitosis. Therefore, PLK1 may also phosphorylate MLL5. We took advantage of the 
difference of gel the migrating mobility between MLL5-CD and MLL5-CD with 
PTMs to examine if MLL5 is a substrate of PLK1. FLAG-MLL5-CD was 
overexpressed in 293T cells synchronized to G2 phase by RO3306 treatment for 16 h 
or to mitosis by nocodazole treatment for 16 h. Mitotic 293T cells were further 
incubated with or without the PLK1 inhibitor, BI2536 for 1.5 h. Western blotting 
results showed that MLL5-CD displayed one single band below 100 kD at G2 phase 
(arrowhead in Figure 3.35). Consistent to previous results, a slower migrating form of 
MLL5-CD4, which is MLL5-CD4 with PTMs appeared after the cells proceeded to 
mitosis (arrow in Figure 3.35). Interestingly, incubation of BI2536 managed to lower 
the upper band slightly, which means that the MLL5-CD4 with PTMs became smaller 
in terms of molecular weight and migrated faster in gel after PLK1 inhibition. This 






































Figure 3.35 The slower-migrating form of FLAG-MLL5-CD migrates faster after 
BI2536 treatment. 293T cells overexpressing FLAG-MLL5-CD was synchronized to 
G2 phase by 16 h RO3306 treatment or mitosis by 16 h nocodazole incubation. The 
mitotic cells were subsequently incubated with or without BI2536 for another 1.5 h. 
The cell lysates were subjected to western blotting probed mouse by anti-FLAG 
antibody. Arrowhead indicates the faster-migrating form of FLAG-MLL5-CD and 
arrow indicates the slower-migrating form of FLAG-MLL5-CD. Diagram illustrates 
the respective MLL5-CD migration patterns for the blot on the left. Red bar indicates 









To acquire a better separation of bands with different migration mobility in gel, we 
overexpressed FLAG-MLL5-CD4 in 293T cells and performed the gel mobility shift 
assay again. After synchronized to G2 or mitosis, mitotic cells were further incubated 
with or without BI2536 for 1.5 h. In line with the results of MLL-CD, the slowest 
migration form of MLL5-CD4 also migrated faster to a lower position in gel after the 
inhibition of PLK1 (Figure 3.36). This further elucidates that PLK1 phosphorylated 
MLL5 and the phosphorylation could be abrogated by BI2536 treatment.  Moreover, 
the phosphorylation site on MLL5 is within CD4 fragment of MLL5. 
 
The above findings suggest phosphorylation of MLL5 by PLK1. To directly 
substantiate this, we performed an in vitro PLK1 kinase assay. GST or GST-tagged 
MLL5-CD4 was transformed into E. coli (BL21) and purified from bacterial culture 
after induction with IPTG. In vitro kinase assay was performed with [γ-32P] ATP. 
Autoradiography and Coomassie Brilliant Blue (CBB) staining results showed that 
PLK1 phosphorylated both GST-MLL5-CD4 and casein, which served as a positive 
control but not GST. Furthermore, addition of BI2536, the PLK1 inhibitor, 
significantly prevented the phosphorylation of both GST-MLL5-CD4 and casein 
(Figure 3.37). To identify the specific PLK1 phosphorylation site on MLL5, we 
dissolved the kinase assay products on a 10% SDS-PAGE gel. After CBB staining, 
protein bands of GST-MLL5-CD4, which had been incubated with PLK1 in the 
presence or absence of BI2536 were excised and analyzed by mass spectrometry (MS) 
using a 5600 TripleTOF analyser. Only one phosphorylation of Ser-861 within MLL5-
CD4 was identified by MS (Figure 3.38).  
 















Figure 3.36 The slowest-migrating form of FLAG-MLL5-CD4 migrates faster 
after BI2536 treatment. 293T cells overexpressing FLAG-MLL5-CD4 was 
synchronized to G2 phase by 16 h RO3306 treatment or mitosis by 16 h nocodazole 
incubation. The mitotic cells were subsequently incubated with or without BI2536 for 
another 1.5 h. The cell lysates were subjected to western blotting probed by mouse 
anti-FLAG antibody. Arrowhead indicates the fastest-migrating form of FLAG-
MLL5-CD4 and arrow indicates the slowest-migrating form of FLAG-MLL5-CD4. 
Diagram illustrates the respective MLL5-CD4 migration patterns for the blot on the 






















Figure 3.37 PLK1 phosphorylates MLL5 in vitro. Upper panel, 32P autoradiograph 
of in vitro PLK1 kinase assay. GST-MLL5-CD-4 purified from E.coli (BL21) was 
subjected to a PLK1 in vitro kinase assay. BI2536 was introduced as an acute inhibitor 
of PLK1. GST and casein served as negative and positive controls, respectively. 





















Figure 3.38 PLK1 phosphorylates MLL5 on Ser-861. Tandem mass spectrometry of precursor ions in the phosphorylated MLL5-CD4 peptide 
(amino acids 854–873; sequence SPLLNDS[Pho]C[CAM]SLPDLTTPLKK where 'S[Pho]' indicates phosphorylated serine and C[CAM] 
indicates carbamidomethylated cysteine) at a m/z of 764.72 Da. Black broken lines (top) indicate peptide cleavage. 
 




In vitro kinase assay and MS have suggested that PLK1 phosphorylates MLL5 on Ser-
861. To confirm this, Ser-861 was converted to alanine by site-directed mutagenesis 
and FLAG-MLL5-CD4-S861A was overexpressed in 239T cells. The cells were 
subsequently synchronized to interphase by RO3306 treatment or mitosis by 
nocodazole treatment. The mitotic cells were further incubated with or without 
BI2536. Although FLAG-MLL5-CD4-S861A still displayed multiple slower-
migrating forms in mitotic cells, the slowest form indicated by arrow moved equally 
fast in the presence or absence of BI2536 (Figure 3.39). This indicates that the 
mutation of S861A had already prevented PLK1 from phosphorylating MLL5, which 
made further inhibition of PLK1 by BI2536 ineffective. Collectively, PLK1 
phosphorylates MLL5 on Ser-861.  
 
Normally, PLK1 binds to the docking site of its substrate through its PBD, which 
relieves the kinase domain from the PBD, enhancing its kinase activity and PLK1 
subsequently phosphorylates the substrate. Since PLK1 binds to the Thr887-Ser888-
Thr889 motif on MLL5 and phosphorylates MLL5 on Ser-861. It is necessary to 
figure out if the PBD binding to TST887 is essential for the phosphorylation of Ser-
861. To this end, the TST887AAA mutant was employed again. After overexpression 
of FLAG-MLL5-CD4-TST887AAA in 293T cells, the cells were synchronized to G2 
phase or mitosis and incubated with or without BI2536. Similar to the results of wild-
type MLL5-CD4, during mitosis, the slowest migrating form of MLL5-CD4 with 
TST887AAA mutation indicated by arrow moved faster to a lower position after the 
inhibition of PLK1 (Figure 3.40). This suggests that PLK1 could still phosphorylate 
MLL5 without binding to the TST887 motif on MLL5. Thus, the PBD binding to 
TST887 and PLK1 phosphorylation of Ser-861 are probably two independent events. 


















Figure 3.39 The slowest-migrating form of FLAG-MLL5-CD4-S861A migrates 
equally fast in the presence or absence of BI2536. 293T cells overexpressing 
FLAG-MLL5-CD4-S861A was synchronized to G2 phase by 16 h RO3306 treatment 
or mitosis by 16 h nocodazole incubation. The mitotic cells were subsequently 
incubated with or without BI2536 for another 1.5 h. The cell lysates were subjected to 
western blotting probed by mouse anti-FLAG antibody. Arrowhead indicates the 
fastest-migrating form of MLL5-CD4-S861A and arrow indicates the slowest-
migrating form of MLL5-CD4-S861A. Diagram illustrates the respective MLL5-

















Figure 3.40 The slowest-migrating form of FLAG-MLL5-CD4-TST887AAA 
migrates faster after BI2536 treatment. 293T cells overexpressing FLAG-MLL5-
CD4-TST887AAA was synchronized to G2 phase by 16 h RO3306 treatment or 
mitosis by 16 h nocodazole incubation. The mitotic cells were subsequently incubated 
with or without BI2536 for another 1.5 h. The cell lysates were subjected to western 
blotting probed by mouse anti-FLAG antibody. Arrowhead indicates the fastest-
migrating form of CD4-TST887AAA and arrow indicates the slowest-migrating form 
of CD4-TST887AAA. Diagram illustrates the respective CD4-TST887AAA 
migration patterns for the blot on the left. Red bar indicates the slowest migrating 
form of CD4-TST887AAA.  




3.7 Exogenous overexpression of MLL5 but not the S888A mutant rescues cells 
from PLK1 mislocalization and aMTOC formation in MLL5-KD cells 
 
Down-regulation of MLL5 led to PLK1 dissociation from centrosome and formation 
of cytosolic aggregates during mitosis. To assess if the PLK1 PBD binding to the 
Thr887-Ser888-Thr889 motif on MLL5 and the phosphorylation of MLL5 on Ser-861 
by PLK1 is crucial for PLK1 centrosomal localization, we generated three full-length 
FLAG-MLL5 mutants: (1) S861A, which could not be phosphorylated by PLK1; (2) 
S888A, which lost the interaction with the PLK1 PBD and (3) S861A-S888A, which 
could neither be phosphorylated by PLK1 nor bind to the PBD of PLK1. Wild-type 
FLAG-MLL5 or MLL5 mutant was introduced to MLL5-KD 293T cells 16 h after 
siRNA transfection. After 8 h incubation, the cells were subsequently synchronized to 
prometaphase by 16 h monastrol treatment to achieve prometaphase synchronization 
with monopolar spindle formation. The cells were then fixed for immunofluorescence 
staining for PLK1 and FLAG. Cells arrested at prometaphase showed characteristic 
monopolar spindles with the centrosome located at the center of the cell, as indicated 
by the presence of centrosomal FLAG-MLL5, despite the lack of other centrosome 
marker (Figure 3.41C-F). Therefore, PLK1 foci in the periphery of the cell, exclusive 
of DNA staining, were considered cytosolic aggregates. In concert with previous 
results, distinct cytosolic aggregates of PLK1 were observed after the knockdown of 
MLL5 (Figure 3.41A, B, G). Moreover, ectopic introduction of wild-type MLL5 
efficiently rescued the PLK1 mislocalization as evident by a decrease of the 
proportion of cells with PLK1 cytosolic aggregates from 60.0% to 22.0% (p < 0.001) 
(Figure 3.41C, G). Similarly, only 23.0% of MLL5-KD cells overexpressing MLL5-
S861A, which was incapable of being phosphorylated by PLK1, showed PLK1 





aggregates (Figure 3.41D, G). This implies that PLK1 phosphorylating MLL5 on Ser-
861 was dispensable for the prevention of PLK1 mislocalization. However, 
overexpression of either MLL5-S888A or MLL5-S861A-S888A, to which the PLK1 
PBD could not bind, failed to decrease the percentage of cells with PLK1 cytosolic 
aggregates to a level comparable to the control cells (Figure 3.41E-G), indicating that 
the PLK1 PBD interaction with MLL5 is critical for proper PLK1 localization.  
 
Likewise, knockdown of MLL5 caused reduction in fluorescence intensity of 
centrosomal PLK1 (Figure 3.41A, B, H) and ectopic introduction of wild-type MLL5 
or MLL5-S861A successfully rescued such reduction (p < 0.001) (Figure 3.41C, D, 
H). This implies that PLK1 phosphorylating MLL5 on Ser-861 was dispensable for 
the maintenance of PLK1 centrosomal localization. However, overexpression of either 
MLL5-S888A or MLL5-S861A-S888A, which is incapable of binding to the PLK1 
PBD failed to restore the fluorescence intensity of centrosomal PLK1 (Figure 3.41E, 
F, H), indicating that the PLK1 PBD interaction with MLL5 is crucial for proper 
PLK1 localization to the centrosome. Collectively, PBD binding to MLL5 on Ser-888 
rather than PLK1 phosphorylating MLL5 on Ser-861 was essential for preventing 





















































Figure 3.41 Exogenous overexpression of MLL5 or MLL5-S861A but not MLL5-
S888A or MLL5-S861A-S888A rescues PLK1 mislocalization in MLL5-KD cells. 
(A-B) 293T cells were transfected with NC- or MLL5-siRNA for 24 h and 
synchronized to prometaphase by 16 h monastrol treatment. The cells were then 
immunostained with mouse anti-FLAG antibody and rabbit anti-pericentrin. DNA was 
counterstained with DAPI. (C-F) 293T cells were transfected with NC- or MLL5-
siRNA for 16 h followed by the transfection of FLAG-MLL5 or its mutant for 8 h. 
The cells were then synchronized to prometaphase by 16 h monastrol treatment and 
immunostained for FLAG and PLK1. DNA was counterstained with DAPI. 
Arrowhead indicates PLK1 cytosolic aggregates. The scale bars represent 10 µm. (G) 
Quantitation of the data presented in A-F. The experiments were repeated three times 
(n = 100 cells per sample). Error bars represent s.e.m. ***, p < 0.001. (H) 
Quantitation of centrosomal PLK1 signal at prometaphase in A-F. (a.u., arbitrary 
unit). Fifteen cells were captured per sample manually and mean pixel intensity of 
PLK1 was computed. ***, p < 0.001.  





Besides PLK1 cytosolic aggregates, the knockdown of MLL5 also caused aMTOC 
formation resulting in spindle multipolarity. Furthermore, the mislocalized PLK1 
aggregates might initiate the formation of aMTOCs, since PLK1 localized to all the 
spindle poles including the newly formed ones. To test this hypothesis, we 
overexpressed wild-type MLL5, MLL5-S861A, MLL5-S888A or MLL5-S861A-
S888A again in MLL5-KD cells. After the synchronization to metaphase by 16 h 
nocodazole treatment and 1.5 h MG132 incubation, the 293T cells were fixed and 
immunostained for pericentrin and FLAG. In line with previous results, down-
regulation of MLL5 significantly increased the proportion of cells with multiple 
centrosome (pericentrin foci) from 4.8% to 31.5% (Figure 3.42A, B, G). Moreover, 
overexpression of wild-type MLL5 or MLL5-S861A, which could not be 
phosphorylated by PLK1, successfully rescued the centrosome abnormality. The 
percentage of cells with multiple centrosomes dropped from 31.5% to 10.7% (wild-
type, p = 0.005) or 15.3% (S861A, p = 0.012), respectively (Figure 3.42C, D, G). Yet, 
overexpression of S888A or S861A-S888A double mutant, which could not bind to 
the PBD of PLK1 failed to rescue supernumerary centrosomes, with approximately 
30% of cells still displaying multiple pericentrin foci (Figure 3.42E-G). These results 
revealed that the PLK1 PBD binding to TST887 on MLL5, but not PLK1 
phosphorylation of Ser-861 on MLL5, was essential for the maintenance of spindle 
bipolarity. Furthermore, since S888A mutant rescued neither PLK1 mislocalization 
nor multiple centrosomes in MLL5-KD cells, the formation of aMTOCs was very 
likely to be the result of PLK1 forming cytosolic aggregates due to the loss of PBD 
binding to MLL5. 
  






















































Figure 3.42 Exogenous overexpression of MLL5 or MLL5-S861A but not MLL5-
S888A or MLL5-S861A-S888A rescues multiple centrosomes in MLL5-KD cells. 
(A-B) 293T cells were transfected with NC- or MLL5-siRNA for 24 h and 
synchronized to metaphase by 16 h nocodazole treatment and 1.5 h MG132 
incubation. The cells were then immunostained with mouse anti-FLAG antibody and 
rabbit anti-pericentrin antibody. DNA was counterstained with DAPI. (C-F) 293T 
cells were transfected with NC- or MLL5-siRNA for 16 h followed by the transfection 
of FLAG-MLL5 or its mutant for 8 h. The cells were then synchronized to metaphase 
by nocodazole-MG132 treatment and immunostained with mouse anti-FLAG 
antibody and rabbit anti-pericentrin antibody. DNA was counterstained with DAPI. 
The scale bars represent 10 µm. (G) Quantitation of the data presented in A-F. The 
experiments were repeated three times (n = 100 cells per sample). Error bars represent 
s.e.m. *. p < 0.05. **. P < 0.01. ***, p < 0.001. 
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CHAPTER 4 – DISCUSSION 
 
4.1 Summary of results 
MLL5 has been implicated to act as a tumor suppressor by regulating cell cycle 
progression. Previously, MLL5 was demonstrated to contribute to the maintenance of 
genomic stability by stabilizing CPC at the kinetochore. MLL5-KD cells displayed 
serious mitotic failure with chromosome misalignment. However, the mechanisms of 
MLL5-CPC interaction are not sufficient to explain the spindle multipolarity defect 
(Liu et al., 2012). Therefore, in this study we further reveal a novel role of MLL5 in 
centrosome regulation and the maintenance of bipolar spindle during mitosis.  
 
We first identified MLL5 as a novel centrosome component by fluorescence 
microscopy and confirmed such subcellular localization of MLL5 by sucrose-gradient 
ultracentrifugation. Moreover, co-IP revealed a strong interaction between MLL5 and 
γ-tubulin, one centrosome marker. Further down-regulation of MLL5 mediated by 
siRNA transfection showed multipolar spindle with multiple centrosome markers 
(PCM foci), which was due to centriole-independent aMTOC formation. Moreover, 
PLK1, a key mitotic kinase, dissociated from the centrosome and formed cytosolic 
aggregates in MLL5-KD cells, which were subsequently present in all spindle poles 
including the original two MTOCs. This suggests an involvement of the PLK1 
aggregates in the formation of aMTOC. Furthermore, cytosolic MLL5 but not 
centrosomal MLL5 was required for the prevention of aberrant aggregation of PLK1 
and subsequent spindle multipolarity. Molecular studies revealed that PLK1 bound to 
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the Thr887-Ser888-Thr889 motif on MLL5 via the PBD and phosphorylates MLL5 
on Ser-861, which was independent of PBD binding to TST887. Finally, rescue 
experiments demonstrated that the PBD binding to MLL5 was crucial for both proper 
PLK1 localization and spindle bipolarity. Collectively, MLL5 contributes to bipolar 
spindle formation during mitosis by preventing PLK1 from aberrant cytosolic 
aggregation. 
 
4.2 A working model 
MLL5 localizes to the centrosome throughout the cell cycle. PLK1 PBD binding to 
the Thr887-Ser888-Thr889 motif on MLL5 keeps PLK1 in a non-aggregated form in 
the cytosol at prometaphase and facilitates its incorporation to the centrosome during 
mitosis (Figure 4.1A). In the absence of MLL5, the interaction between MLL5 and 
PLK1 is abolished, resulting in less soluble PLK1 in the cytosol. PLK1 therefore 
aggregates rather than being recruited to the centrosome. Some of these aggregates 
subsequently turn into aMTOCs, leading to spindle multipolarity at metaphase (Figure 
4.1B). 
  


















Figure 4.1 Proposed working model for the role of MLL5 in maintaining spindle 
bipolarity. (A) Normal bipolar spindle formation. Pc, pericentrin; M5, MLL5; γ-
TuRC, γ-tubulin ring complex. (B) Multipolar spindle formation in cells without 
MLL5. aMTOC, acentrosomal MTOC; PLK1*, PLK1 aggregates. 
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4.3 MLL5 and spindle bipolarity 
During mitosis, the two centrosomes ensure the bipolarity of mitotic spindle, which is 
critical for accurate chromosome segregation in anaphase and subsequent 
cytokineisis. Abnormal centrosome number and spindle multipolarity in mitotic cells 
are hallmarks of cancers, leading to CIN and aneuploidy. Down-regulation of MLL5 
caused a drastic increase in the proportion of cells displaying multipolar spindle with 
multiple centrosome markers. Normally, centrosome amplification caused by centriole 
over-duplication or cytokinesis failure is able to result in spindle multipolarity. 
Without centrosome amplification, spindle multipolarity can also arise from centriole 
disengagement or PCM fragmentation (Maiato and Logarinho, 2014). In MLL5-KD 
cells, the two pairs of centrioles were not affected. Time-lapse microscopy further 
ruled out the possibility of centrosome fragmentation and revealed that the spindle 
multipolarity after MLL5 knockdown actually resulted from aMTOC formation. 
 
The assembly of γTuRC at the centrosome nucleating microtubules marks the 
conversion of the centrosome to the MTOC. PLK1 plays a vital role in this process. It 
not only recruits γ-tubulin to the centrosome but also phosphorylates NEDD1 and 
HICE1, which promotes augmin-microtubule interaction and targets the γ-TuRC to 
the centrosome (Luders et al., 2006; McInnes et al., 2006; Zhang et al., 2009a). 
Besides centrosome-based microtubule nucleation, PLK1 also regulates microtubule-
based microtubule nucleation (Johmura et al., 2011). Since PLK1 formed cytosolic 
aggregates in MLL5-KD cells at prometaphase (Figure 3.16), it is likely that 
mislocalized PLK1 served as additional nucleation sites, organizing microtubules and 
subsequent mitotic spindle. Indeed, when MLL5-KD cells proceeded to metaphase, 
PLK1 localized to all the spindle poles including the newly formed ones (Figure 
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3.18). Moreover, MLL5 incapable of binding to the PBD of PLK1 failed to rescue 
either PLK1 cytosolic aggregates or multiple centrosomes in MLL5-KD cells, further 
confirming the hypothesis that mislocalized PLK1 aggregates lead to aMTOCs. 
Likewise, NUMB-knockdown cells display similar mislocalized PLK1 aggregates, 
which associated with γ-tubulin (Schmit et al., 2012). Although SENP6-knockdown 
cells also display cytosolic aggregates of PLK1, no spindle multipolarity was 
observed (Mukhopadhyay and Dasso, 2010). This is probably owing to PLK1 
dissociation from the kinetochore rather than the centrosome in SENP6-KD cells.  
 
In MLL5-KD cells, PLK1 aggregates could be observed at prometaphase (Figure 
3.16). However, PCM proteins were not recruited to PLK1 aggregates until metaphase 
(Figure 3.18). This is probably because the prometaphase synchronization by 
nocodazole or monastrol treatment blocked the movement of PCM proteins along 
microtubules. Additionally, in MLL5-KD cells, not all cytosolic PLK1 aggregates 
were able to form extra MTOCs, most likely due to insufficient kinase activity or 
binding ability of the PBD. Detailed mechanisms of PLK1 aggregate formation 
causing aMTOC organization need further investigation. 
 
The kinase activity of PLK1 is required for its recruitment to the centrosome (Lenart 
et al., 2007; Haren et al., 2009). Consistently, after we treated metaphase U2OS cells 
with BI2536, mitotic cells became monopolar and PLK1 dissociated from the 
centrosome, forming cytosolic aggregates (Figure 24A). Considering that PLK1 has a 
number of substrates and binding partners, we speculate that loss of interaction 
between PLK1 and its interacting proteins could possibly make cytosolic PLK1 less 
soluble and prone to aggregation. Thus, less amount of PLK1 can be recruited to the 
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kinetochore or the centrosome. Depletion of kinetochore-localized SENP6 resulted in 
PLK1 aggregates with reduced intensity of PLK1 at the kinetochore (Mukhopadhyay 
and Dasso, 2010). On the other hand, knockdown of Numb causes PLK1 aggregation 
and impairs PLK1 spindle pole localization at both metaphase and anaphase (Schmit 
et al., 2012). In this study, knockdown of MLL5 disrupted the cytosolic interaction 
between MLL5 and PLK1, resulting in aberrant aggregation of PLK1 and partial 
dissociation from the centrosome. However, we also noted that endogenous MLL5 in 
BI2536-treated mitotic cells associated with PLK1 aggregates, suggesting a strong 
interaction between MLL5 and PLK1 that is kinase-activity independent (Figure 24). 
 
4.4 Interaction between MLL5 and PLK1 
PLK1 is initially activated by Aurora A kinase phosphorylation on Thr-210 in its T-
loop with Bora, introducing a conformational change and disrupting autoinhibition of 
the kinase domain by the PBD (Jang et al., 2002; Macurek et al., 2008; Seki et al., 
2008b). Binding of the PBD to phospho-proteins then induces PLK1 activity by 
further relieving the kinase domain from the PBD (Elia et al., 2003b). In this study, 
we discovered that the PBD of PLK1 binds to the Thr887-Ser888-Thr-889 motif on 
MLL5 and phosphorylates MLL5 on Ser-861. However, the PBD binding and 
phosphorylation appear to be two independent events. Gel mobility assay showed that 
MLL5 mutant that did not bind to the PBD could still be phosphorylated (Figure 
3.34), while inhibition of PLK1 activity did not abrogate the PLK1 PBD binding to 
MLL5 either (Figure 3.28). In addition, the S888A and the S861A mutants showed 
totally different behaviours in the rescue of PLK1 aggregates and multiple 
centrosomes. Moreover, the S888A-S861A double alanine mutant did not further 
reduce the percentage of cells with PLK1 aggregates or multiple centrosomes 
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compared to the S888A single mutant (Figure 3.35-3.36). Yet, we still cannot 
eliminate the possibility that the PBD binding to MLL5 makes PLK1 more active or 
that Ser-861 may not be the only site phosphorylated by PLK1, even though mass 
spectrometry did not detect any other phospho-site besides Ser-861 within MLL5-
CD4 after in vitro PLK1 kinase assay. 
 
Notably, the PLK1 PBD binding motif on MLL5, Thr887-Ser888-Thr889 together 
with Pro-990 falls into the consensus PBD-binding sequence (Τ/Q/H/M-S-pT/pS-P/X, 
where X stands for any amino acid) (Elia et al., 2003a; Lowery et al., 2007). 
However, the mutation of Ser-888 to alanine and to aspartic acid mimicking 
phosphorylation both abrogated the interaction between MLL5 and PLK1 (Figure 
3.28), indicating that phosphorylation of Ser-888 may not be required for the PLK1 
PBD binding. On the other hand, although CDK1 phosphorylation of MLL5 on Thr-
912 does not serve as a docking site for the PBD binding, inhibition of CDK1 by 
RO3306 treatment abrogated the PBD binding to MLL5-CD4 (Figure 3.28). It is 
likely that CDK1 does not phosphorylate the PBD binding site itself, but activates a 
downstream kinase, which is responsible for the PLK1 PBD binding to MLL5. 
Discovery of such a kinase would greatly advance our knowledge of PBD-mediated 
PLK1 function. 
 
PLK1 PBD binding to phospho-peptides is believed to target PLK1 to specific 
subcellular localizations, including the centrosome (Elia et al., 2003a). However, 
Hanisch et al. showed that the PBD of PLK1 is dispensable during centrosome 
maturation (Hanisch et al., 2006). Another study found that the recruitment of PLK1 
to the centrosome at the late G2 phase, which initiates centrosome maturation, is 
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dependent on PLK1 phosphorylation of pericentrin (Lee and Rhee, 2011). Yet, this 
does not rule out the presence of alternative mechanisms for recruitment of PLK1 to 
the centrosome. In this study, we demonstrate that the interaction between MLL5 and 
PLK1, in particular the PLK1 PBD binding to the Thr887-Ser888-Thr889 motif on 
MLL5, is crucial for the prevention of aberrant cytosolic PLK1 aggregation and 
centrosomal localization of PLK1. Although such binding occurs in the cytosol during 
mitosis, the centrosome-localized MLL5 may also interact with PLK1 and contribute 
to the incorporation of PLK1 into the centrosome. In addition, we observed that a 
faster-migrating form of FLAG-MLL5-CD (Figure 3.26), which is MLL5 with 
relatively less PTMs maintained its ability to interact with PBD-mutated PLK1. This 
indicates that other PLK1 binding sites on MLL5 are also likely to exist.  
 
4.5 MLL5 and tumor suppression 
Genomic instability or CIN during mitosis resulting in aneuploidy has long been 
considered a driving force of tumorigenesis. Previously, MLL5 was discovered to 
maintain mitotic fidelity by stabilizing CPC at the kinetochore. Knockdown of MLL5 
results in CPC delocalizing from the kinetochore, leading to genomic instability and 
CIN. Moreover, MLL5-KD cells undergo mitotic slippage, exiting mitosis without 
proper chromosome segregation, which results in aneuploidy (Liu et al., 2012). These 
findings all suggest the role of MLL5 in tumor suppression. Here, we further 
demonstrate that MLL5 is a novel centrosomal protein and is essential for bipolar 
spindle formation. In the absence of MLL5, cells encounter abnormal mitosis 
displaying multipolar spindle with multiple centrosomes, a hallmark of cancer. From 
the very beginning, MLL5 has been implicated to be a tumor suppressor as 
perturbation of MLL5 level causes cell cycle arrest (Deng et al., 2004; Cheng et al., 
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2008). In addition, CDK1 phosphorylation of MLL5 is required for mitotic entry (Liu 
et al., 2010b). MLL5 is also a novel component in the regulation of p53 homeostasis, 
and down-regulation of MLL5 by anti-cancer drug camptothecin causes the activation 
of TP53 in a various human cell lines (Cheng et al., 2011). However, Mll5 is not a 
proto-oncogene like TP53, as no spontaneous tumorigenesis has been observed in 
Mll5-knockout mice so far (Heuser et al., 2009; Madan et al., 2009; Zhang et al., 
2009b). Yet, other leukemia-related genes such as Runx1/Aml1 also encounter the 
same situation and acquisition of additional hits is required for the leukemogenesis 
(Rhoades et al., 2000; Yuan et al., 2001). Growing evidence has shown that 
dysfunction of histone modification mediator and resulting misregulation of histone 
modification actively contribute to tumorigenesis (Chi et al., 2010). Recently, the 
PHD finger of MLL5 was found to interact with and read di- and tri-methylated 
histone H3K4 (Ali et al., 2013). Finally, clinical study of AML patients has revealed a 
correlation between high expression level and favourable prognostic outcome (Damm 
et al., 2011). Taken together, MLL5 is a potential tumor suppressor gene, playing 
important roles in the maintenance of mitotic fidelity and the prevention of genomic 
instability. 
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CHAPTER 5 – FUTURE DIRECTION 
 
5.1 PTMs on MLL5  
Endogenous MLL5 displays slower gel mobility upon mitosis due to phosphorylation 
(Liu et al., 2010b). Here, multiple slow-migrating forms of MLL5-CD4 in mitotic 
cells clearly indicate multiple phosphorylations added on MLL5. Indeed, mass 
spectrometry identified 22 phosphorylated sites within the central domain of MLL5 
(data not shown). It is possible that MLL5 serves as a master substrate for various 
mitotic kinases. Previously, MLL5 was discovered as a substrate of CDK1 (Liu et al., 
2010b). Here, we further identified MLL5 to be phosphorylated by PLK1. Among the 
PLK family, PLK2 and PLK4 have been clearly demonstrated to regulate centriole 
duplication (Warnke et al., 2004; Bettencourt-Dias et al., 2005). In addition, a number 
of kinases other than PLKs including Aurora A and Nek2, have also been shown to 
affect normal centrosome function or spindle bipolarity (Giet and Prigent, 2000; 
Garrett et al., 2002; Kufer et al., 2002; Eyers et al., 2003; Marumoto et al., 2003; 
Prigent et al., 2005; Asteriti et al., 2011; Cappello et al., 2013). Whether MLL5 plays 
a similar role in recruiting these kinases to the centrosome remains to be seen. 
Moreover, the PBD of PLK1 only interactes with the slowest-migrating form of 
MLL5-CD4 indicates a certain PTM, probably phosphorylation, which is required for 
the PBD binding. Discovery of a pro-directed kinase responsible for the 
phosphorylation by either co-IP followed by MS or co-IP combined with inhibitor 
screening will greatly broaden our scope on PLK1 PBD regulation. Thus, further 
exploration of the role of MLL5 interacting with other kinases in regulating the 
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centrosome or other functions in mitosis will strengthen our understanding of the 
critical mechanisms, by which faithful bipolar spindle formation and genomic 
stability are achieved.  
 
Phospho-mimicking mutant of MLL5 (T887E, S888D, T889E) lost interaction with 
the PBD of PLK1 (Figure 3.33). Although phospho-mimicking mutation sometimes 
does not work due to the alteration of the overall structure, we speculate that other 
modifications besides phosphorylation likely contribute to MLL5 interacting with the 
PLK1 PBD. O-GlcNAcylation, acetylation and O-Sulfonation of serine/threonine 
have been discovered to transmit cell signal (Medzihradszky et al., 2004; Mittal et al., 
2006; Mukherjee et al., 2006; Deplus et al., 2013). As mentioned in the introduction, 
O-GlcNAcylation of MLL5β, an N-terminal short isoform of MLL5 was found to be 
required for the assembly of MLL5β-AP-1 transcription complex at the HPV16/18-
long control region (Nin et al., 2015). In addition, O-GlcNAc transferase was 
discovered to cooperatively regulate the protein stability of another MLL5 N-terminal 
isoform with ubiquitin specific protease 7 (Ding et al., 2015). Discovery of PTMs 
required for PBD binding to MLL5 and identification of the enzyme involved would 
greatly advance our knowledge of PBD-mediated PLK1 function. 
 
5.2 MLL5 and spindle assembly checkpoint (SAC) 
Cells that cannot satisfy SAC are arrested at metaphase.  Importantly, in cancer cells, 
SAC is often weakened. Additionally, mitotic slippage due to SAC dysfunction results 
in multinuclear cells, which are hallmarks of cancer cell (Brito and Rieder, 2006). 
MLL5 has been implicated to contribute to SAC, as cell cycle analysis by flow 
cytometry demonstrated that MLL5-KD cells undergo mitotic slippage. BubR1, a key 
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component of SAC, also loses its kinetochore localization after MLL5 knockdown 
(Liu et al., 2012). BubR1, also known as BUB1B or MAD3, plays a central role in 
SAC maintenance. It stabilizes kinetochore–microtubule attachment and contributes 
to chromosome alignment (Meraldi and Sorger, 2005). Although the mitotic slippage 
and BubR1 dissociation from centrosome in MLL5-KD cells might be a secondary 
effect of the degradation of Aurora B, a CPC subunit, which targets BubR1 and Mad2 
to kinetochores, MLL5 itself may directly regulate SAC.  
 
The inhibition of APC/C by SAC is achieved by mitotic checkpoint complex (MCC) 
inhibiting CDC20, an activator of APC/C. MCC is formed by various cytosolic SAC 
proteins including MAD2, BUB3 and BubR1, which function differently from their 
kinetochore counterparts. Immunoprecipitation will help to assess if MLL5 interacts 
with BubR1 and if MLL5 is a component of MCC. Medication of cancer by drugs 
targeting mitosis often encounters the development of resistance owing to mitotic 
slippage. Since high MLL5 expression levels are associated with better prognosis in 
AML (Damm et al., 2011), it is likely that cells with high MLL5 level has lower 
chance undergoing SAC adaptation and thus are less resistant to chemotherapy. 
Therefore, the study of MLL5 and SAC will provide a novel basis for therapeutic 
approach to cancer treatment. 
 
5.3 Non-histone lysine methyltransferase activity of MLL5 
Unlike histone lysine methylation, which has been extensively studied, non-histone 
lysine methylation was only found on very few proteins, among which, p53 is the 
most extensively studied. SET7/9 was first discovered to methylate p53 (Chuikov et 
al., 2004). Subsequently, several lysine methyltransferases (KMTs) and one lysine 
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demetylase, were identified to regulate p53 (Huang et al., 2006; Shi et al., 2007; Chen 
et al., 2010; Huang et al., 2010). These methylations not only interact with other 
PTMs of p53 or regulate p53 binding to other proteins, but also play critical roles in 
vivo (Zhang et al., 2012). Besides p53, a few transcriptional factors including ERα, 
NFκB, E2F1, RB, and STAT3 as well as histone- or DNA-modifying enzymes such as 
DNMT1 and KMT1C have been found to be non-histone KMT substrates. Strikingly, 
SET7/9 which is the only H3K4 mono-KMT identified by far mediates most of these 
methylations (Pradhan et al., 2009). Besides SET7/9, G9a/EHMT2, which specifically 
methylates H3K9 catalyzes lysine methylation of p53, G91, C/EBPβ, Retin, RARα
DNMT1CDYLWIZ and ACINUS (Chin et al., 2007; Huq et al., 2008; Pless et 
al., 2008; Rathert et al., 2008; Lee et al., 2010). Moreover, the NSD1 methylating 
H3K36me2 mediates NFκB methylation (Huang et al., 2006). SMYD is found to 
methylate p53 and Rb, while SMYD3 catalyzes VEGFR methylation (Kunizaki et al., 
2007; Saddic et al., 2010). Although MLL family proteins show HKMT activity on 
H3K4me2 or H3K3me3, none of them has been reported to methylate proteins other 
than histones. However, the SET domain of MLL5β is essential to activate E6 and E7 
transcription in HPV16/18 positive cervical cancer (Yew et al., 2011). Moreover, the 
dynamic localizations of full-length MLL5 suggest a KMT activity on non-histone 
substrates. Identification of a substrate methylated by MLL5 will open up a brand new 
direction for the study of MLL5 and even the entire MLL protein family. 
 
5.4 Clinical relevance of MLL5 in cancer 
MLL5 has been shown to regulate cell cycle in different manners, maintaining 
genomic integrity and spindle bipolarity during mitosis, while down-regulation of 
MLL5 causes cell cycle arrest, chromosome instability and multipolar spindle with 
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multiple centrosomes. More importantly, high MLL5 expression levels are associated 
with better prognosis in AML (Damm et al., 2011). Therefore, as a potential tumor 
suppressor gene, MLL5 protein level may negatively correlate to tumor occurrence or 
the hallmarks of cancer such as aneuploidy and centrosome abnormality. 
Immunohistochemistry staining of MLL5 and centrosome marker protein in tissue 
arrays composed of normal tissue samples and different tumor tissue samples will 
enable us to verify whether MLL5 level is significantly lower in tumor sample than in 
normal tissue sample and whether MLL5 level is negatively correlated with the 
occurrence of centrosome abnormality. Although no spontaneous tumorigenesis has 
been observed in Mll5-knockout mice (Heuser et al., 2009; Madan et al., 2009; Zhang 
et al., 2009b), acquisition of additional hits maybe required for the oncogenesis. 
MEFs isolated from wild-type, Mll5+/- and Mll5-/- mice can be studied for growth rate, 
cell cycle progression, genomic instability and mitotic index. Moreover, the 
application of physical and chemical carcinogen to MEFs will enable us to compare 
any potential phenotype changes including cell cycle delay, aneuploidy and 
centrosome abnormalities among the three types of MEFs. Finally, wild-type, Mll5+/- 
and Mll5-/- mice will be used to explore the physiological function of MLL5. 
Challenging the mice with toxins and carcinogens will help us to reveal whether Mll5-
deficient mice are more sensitive to genotoxicity. 
 
5.5 Conclusion 
In this thesis, we further explored the role of MLL5 in the maintenance of genomic 
stability and studied the molecular mechanism of MLL5 regulating spindle bipolarity 
during mitosis. MLL5 was identified as a novel centrosomal protein besides its 
dynamic nucleus localization. Immunofluorescence showed that such centrosome 
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localization was regardless of cell cycle progression. Immunoprecipitation 
experiments further revealed that MLL5 interacted with one centrosome marker 
protein, γ-tubulin. Knockdown of MLL5 dramatically increased the cells displaying 
multipolar spindles with multiple centrosomes at metaphase due to the formation of 
aMTOCs, which was centriole-independent. Further immunofluorescence delineated 
that the knockdown of MLL5 caused aberrant cytosolic aggregation of one key 
kinase, PLK1. At prometaphase, PLK1 formed cytosolic aggregates and partially 
dissociated from the centrosome in MLL5-KD cells, while at metaphase PLK1 
localized to all the multiple spindle poles, including those newly formed ones. These 
results suggest that cytosolic PLK1 aggregates are involved in the formation of 
aMTOC. Moreover, cytosolic MLL5 rather than centrosomal MLL5 was required for 
the prevention of PLK1 cytosolic aggregation and subsequent multipolar spindle 
formation. Molecular studies elucidated that the PBD of PLK1 bound to the Thr887-
Ser888-Thr889 motif on MLL5 and PLK1 also phosphorylated MLL5 on Ser-861. 
Rescue experiments demonstrated that overexpression of MLL5 but not the MLL5 
mutant incapable of binding to the PBD of PLK1 rescued PLK1 mislocalization and 
multiple centrosomes in MLL5-KD cells. These results indicate that the PLK1 PBD 
binding to MLL5 maintains PLK1 in a non-aggregated form, which is essential for 
bipolar spindle formation during mitosis. 
 
This study reveals a novel role of MLL5 in centrosome regulation during mitosis 
providing more evidence for the maintenance of genomic stability by MLL5. We 
further extend the understanding of how PLK1 is regulated and incorporated to the 
centrosome. Yet, how MLL5 knockdown leads to PLK1 cytosolic aggregates and how 
PLK1 aggregates results in aMTOC formation are still elusive. Moreover, whether 
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PLK1 phosphorylation of MLL5 on Ser-861 has a function in centrosome regulation 
remains to be seen. Since there are multiple phosphorylation sites on MLL5, 
identification of kinases phosphorylating MLL5 will definitely open up new fields of 
MLL5 study. Last but not least, studying the clinical relevance of MLL5 in human 
cancer by either Mll5 knockout mice model or tissue samples from patients will 
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